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Resumo 
A terapia génica é uma estratégia terapêutica que se caracteriza pela entrega de 
material genético a uma célula alvo. A terapia génica tem sido vastamente utilizada no 
combate a diversas doenças genéticas e adquiridas, tais como as doenças 
cardiovasculares, cancro e doenças oculares, entre outras.  
Devido às suas características únicas, como tamanho reduzido, relativo 
isolamento da circulação sistémica e fácil acessibilidade a diferentes tipos celulares e 
tecidos, o olho é considerado o órgão ideal para o desenvolvimento de estratégias de 
terapia génica. A Retinite Pigmentosa e a Retinopatia Diabética são exemplos de 
doenças oculares genéticas e adquiridas, respetivamente, que afetam a retina e 
conduzem a uma perda irreversível de visão. Apesar da sua etiologia ser diferente, 
ambas as patologias partilham o facto de, atualmente, não existir um tratamento 
eficaz, o que faz destas bons alvos para terapia génica.  
Atualmente, cerca de 80% das estratégias de terapia génica usadas para doenças 
oculares são baseadas na utilização de vírus como vetores de entrega do material 
genético. Apesar da sua eficácia, esta abordagem acarreta uma série de 
desvantagens, principalmente do ponto de vista de segurança a nível imunológico e 
mutagénico. Assim, os vetores não-virais aparecem como estratégia alternativa aos 
vetores virais, pela sua fácil utilização, ilimitada capacidade de empacotamento de 
genes e ausência de resposta imunitária. Porém, a sua aplicação clínica encontra-se 
limitada, não só pela sua reduzida eficiência de transfeção como pela expressão 
genética transiente conferida pelos, até agora utilizados, sistemas de expressão. 
Neste sentido, nas últimas décadas têm sido desenvolvidos sistemas de 
expressão baseados em plasmídeos de ADN, que visam uma expressão prolongada, 
como os minicírculos, os vetores MIDGE, os pFARs e os plasmídeos epissomais com 
capacidade de auto-replicação. Exemplos de plasmídeos com capacidade de auto-
replicação são os pEPI-1 e pEPito. Nestes plasmídeos, a capacidade de auto-
replicação é conferida pela presença de S/MARs (Scaffold/Matrix Attachment Regions) 
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no corpo do plasmídeo. As S/MARs são sequências de ADN ricas em nucleótidos 
Adenina (A) e Timina (T) capazes de ancorar a cromatina à matriz nuclear. As S/MARs 
parecem estar envolvidas na destabilização e abertura da dupla hélice de ADN, 
sugerindo um envolvimento na replicação e expressão do mesmo, uma vez que a 
transição de cadeia dupla para cadeia simples é necessária para a replicação e 
transcrição genética. Além disso, vetores com S/MARs são capazes de prevenir o 
silenciamento epigenético, protegendo o transgene das sequências regulatórias 
adjacentes e da heterocromatinização, mantendo o vetor num estado 
transcricionalmente ativo e conferindo, assim, estabilidade mitótica. As S/MARs têm, 
também, a capacidade de mediar a associação da partícula episomal aos 
cromossomas metafásicos, permitindo, assim uma distribuição igualitária dos 
epissomas para as células filhas, após a mitose.  
O objetivo deste trabalho foi desenvolver uma estratégia de terapia génica não-
viral para doenças da retina, recorrendo ao uso de sistemas de expressão epissomais 
com capacidade de auto-replicação (pEPito) e de um sistema de entrega eficaz 
(eletroporação), de modo a conseguir uma expressão prolongada dos genes 
terapêuticos. Experimentalmente é possível dividir este trabalho em três secções: i) 
identificação de genes com potencial terapêutico em patologias da retina, como RP e 
RD; ii) clonagem dos genes em questão em vectores epissomais, pEPito e iii) 
administração dos vetores desenvolvidos in vivo, na retina de ratinhos, utilizando 
eletroporação como método de entrega dos sistemas de expressão.  
Foi recentemente descrito em ratinhos que mutações no gene ATR (Ataxia 
telangiectasia and Rad3 related) induzem uma acumulação de pigmento na retina, 
com consequente degeneração dos fotorrecetores (bastonetes e cones), semelhante à 
que acontece em pacientes com Retinite Pigmentosa. Nos animais Wild-Type esta 
proteína está localizada nos cílios dos fotorrecetores. Nos mutantes, a presença da 
proteína mutada induz um encurtamento dos cílios, originando uma degeneração dos 
bastonetes e, posteriormente, dos cones. Neste contexto, tentámos investigar qual a 
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função desta proteína na formação e alongamento dos cílios retinianos. Os nossos 
estudos in vitro demonstraram que esta proteína está associada ao centrossoma das 
células ciliadas. Nestas células, o centrossoma é o local onde o cílio se forma e por 
onde começa a alongar. A inibição de ATR (pela cafeína) originou uma diminuição da 
expressão proteica e, como consequência, verificou-se uma diminuição no 
comprimento dos cílios das células tratadas, demonstrando uma relação direta entre a 
expressão de ATR e a função ciliar. Assim, podemos inferir que mutações no gene 
ATR podem ser responsáveis por alguns dos casos de RP que não estão associados 
aos genes normalmente implicados na doença. 
A Retinopatia Diabética é uma das principais complicações da Diabetes Mellitus. 
É considerada uma doença das barreiras hematorretinianas, na qual a hiperglicemia e 
isquémia são as principais responsáveis pelo desequilíbrio entre os fatores pro- e anti-
angiogénicos que conduzem à neovascularização e consequente perda de visão. 
Neste estudo avaliámos os efeitos da hiperglicemia e isquémia na barreira 
hematorretiniana externa, in vitro, em culturas de células do epitélio pigmentar da 
retina, sujeitas a glicose elevada e in vivo, no epitélio pigmentar da retina de ratinhos 
diabéticos Ins2Akita. Os nossos resultados mostraram um aumento do transportador de 
glicose (GLUT1) nos nossos modelos diabéticos. Este aumento está associado, não 
só, a um aumento no número de transportadores na membrana das células do epitélio 
pigmentar da retina, como também a um aumento da sua atividade, aumentando o 
consumo de glicose. Este aumento no consumo de glicose induz uma diminuição na 
produção e secreção de factores anti-angiogénicos, como o PEDF (Pigment 
Epithelium-Derived Factor) por estas células. Esta diminuição contribui para o 
desequilíbrio entre os fatores pro- e anti-angiogénicos, contribuindo assim para o 
desenvolvimento da neovascularização. 
Baseado nos resultados anteriores, decidimos clonar o gene PEDF no vetor de 
expressão pEPito e, através de injeção subretiniana, administrá-lo nas células do 
epitélio pigmentar da retina de ratinhos Ins2Akita. Os nossos resultados mostraram que 
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os nossos vetores foram capazes de sobre-expressar PEDF até três meses após a 
injeção, em níveis semelhantes aos dos animais controlo (não diabéticos). Esta sobre-
expressão foi associada a uma diminuição de marcadores inflamatórios e 
angiogénicos, associados à doença. Estes resultados mostram que a sobre-expressão 
de PEDF pode constituir uma nova estratégia para o tratamento da RD. 
Os nossos resultados indicam que esta abordagem baseada em sistemas de 
expressão com capacidade de auto-replicação e menos susceptíveis ao silenciamento 
epigenético, como os pEPito, aliada a um método de entrega de ADN eficaz, como a 
eletroporação, pode ultrapassar as limitações associadas à utilização de vetores virais, 
conferindo um padrão de expressão génica prolongado e mantendo um elevado perfil 
de segurança, consistindo assim numa alternativa eficaz para a terapia génica 
retiniana. 
 
 
Palavras-chave: Terapia génica; pEPito; S/MARs, Retinite Pigmentosa; Retinopatia 
Diabética 
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Abstract 
Retinitis Pigmentosa (RP) and Diabetic retinopathy (DR) are blinding disorders that 
contribute to 25 to 30% of blindness cases in work-age people. The ineffectiveness of 
current treatments makes them ideal targets for gene therapy. The gene therapy 
strategy should include the main advantages of viral vectors – long-term expression 
and high transduction capacity – without presenting its disadvantages – immune 
response, random integration and tumor formation. This can be achieved by using self-
replicating episomal vectors, such as pEPito.  
The goal of this project was to develop new strategies using pEPito vectors 
encoding therapeutic genes for retinal diseases, such as DR and RP.  
RP is an inherited degenerative disease, characterized by loss of photoreceptors. 
Recently, depletion of ATR in the mouse retina was associated to a RP-like phenotype. 
Our results show that, in ciliated cells, ATR is localized in the centrosome, 
corresponding to the connecting cilium. The inhibition of ATR induced a decrease in 
cilia length, showing a direct relationship between ATR and cilia formation and 
elongation. These findings suggest ATR as a new therapeutic target for RP.  
DR is the main complication of diabetes. Several studies have shown an 
imbalance between pro- and anti-angiogenic factors, due to ischemia and 
hyperglycemia. In this work we describe an impairment of the oBRB due to an increase 
GLUT1 expression and function, in diabetic models. As a consequence, we detected a 
decrease in PEDF production and secretion. We decided to clone PEDF into pEPito 
backbone and overexpressed it in Ins2Akita diabetic mice, using subretinal injection and 
electroporation. Our system showed sustained gene expression for up to three months 
in levels comparable to WT mice. The overexpression of PEDF was associated with a 
decrease in several inflammatory and angiogenic factors associated with DR. 
Our results indicate that the pEPito-based approach, combined with 
electroporation may overcome some limitations found in viral-mediated gene transfer, 
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while maintaining a high safety profile and sustained gene expression, thus constituting 
an alternative for retinal gene delivery. 
 
 
Keywords: Gene Therapy, pEPito, S/MARs, Retinitis Pigmentosa, Diabetic 
Retinopathy 
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1.1 Gene Therapy 
Gene therapy is a therapeutic strategy that involves intracellular delivery of 
exogenous genetic material (DNA or RNA) to correct or modify the expression of genes 
responsible for a certain genetic or acquired disease (Naik et al., 2009, Ramamoorth et 
al., 2015). Depending on the disease, this can be achieved by: 
 Replacement of a mutated gene that causes a disease by a correct copy of the 
gene (Kaufmann et al., 2013, Ramamoorth et al., 2015); 
 Inactivation of a malfunctioning mutated gene by using antisense RNA that 
binds to the messenger RNA (mRNA) blocking it, or by using the siRNA (small 
interfering) technology, a class of double-stranded RNA molecules that 
neutralizes the mRNA transcript, resulting in no translation into protein 
(Kaufmann et al., 2013, Ramamoorth et al., 2015); 
 Introduction of new genes, a strategy that is being widely used in cancer gene 
therapy in which the insertion of specific genes induces the host cell to enter 
apoptosis (Kaufmann et al., 2013, Ramamoorth et al., 2015). 
 The ideal gene therapy strategy includes four basic prerequisites: i) it should be 
efficient and nontoxic, ii) the targeted disease should be well characterized in terms of 
genetic defect and the tissue/ cell types affected, iii) the expression levels of the 
therapeutic gene must be tightly controlled, and iv) an adequate animal model should 
be available for pre-clinical studies and proof-of-concept (Hauswirth et al., 2000). 
Since the first approved clinical trial in 1990 for the treatment of SCID (Severe 
Combined Immunodeficiency), using ADA (Adenosine Deaminase) gene (Blaese et al., 
1995), several disorders, either genetic or acquired, have been targeted using gene 
therapy, namely cancer, cardiovascular diseases and ocular diseases (Figure 1.1) 
(Gascón et al., 2013, Kaufmann et al., 2013, Ramamoorth et al., 2015). 
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Figure 1.1: Targeted diseases in gene therapy clinical trials. Cancer is the most 
representative disorder in gene therapy applications, but cardiovascular, infectious and 
monogenic diseases are also noteworthy. Adapted from (Gascón et al., 2013). 
 
The ideal vehicle for gene therapy should penetrate the cell membrane and 
efficiently deliver genes specifically into target cells, without being toxic or 
immunogenic. The genes must be directed to the nucleus and integrate the host 
genome in a non-mutagenic way or be maintained as an episome for a long time 
period. It is also desirable the therapeutic gene to be delivered independently of the 
mitotic status of the recipient target cell and the expression level should be constant 
over time (Chaum et al., 2002, Gascón et al., 2013). 
 
1.2. The eye as target for gene therapy 
The eye is the organ responsible for the vision. It consists of two distinct anatomic 
regions: the anterior cavity and the posterior cavity (Figure 1.2) (de la Fuente et al., 
2010).  
The anterior cavity is the segment between the cornea and the lens, including the 
conjunctiva. These structures are responsible for focusing the light on the 
photoreceptor cells of the retina, in the posterior cavity of the eyeball, allowing vision. 
The cornea is a non-vascularized tissue composed by five to seven layers, conferring 
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high resistance to passive diffusion of ions and molecules. It is also responsible for 
enduring the intraocular pressure (de la Fuente et al., 2010). 
Figure 1.2: Schematic representation of the eye with an enlargement of the retina, 
showing its main cells types. Based on (Farjo et al., 2010). 
 
The posterior cavity is the space between the lens and the sclera, including the 
retina and choroid. The posterior cavity contains the vitreous humor, a gel-like 
substance composed of water, collagen, hyaluronic acid and proteoglycans. The 
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vitreous humor acts as a shock absorber, supports the shape of the eye, and is in 
contact with the retina, keeping it in place by pressing it into the choroid. The sclera is a 
hard tissue composed mainly by connective tissue. It is also responsible for 
maintaining the structure of the eye, by resisting intraocular pressure. The choroid is a 
vascular layer responsible for providing blood supply to retinal cells (Colthurst et al., 
2000).  
The retina is the most metabolically active tissue of the human body, with a fast 
rate of glucose and oxygen consumption. It is the sensory tissue that lines the inner 
surface of the posterior segment of the eye and is organized in seven major layers 
composed mainly by three cell types (Naik et al., 2009):  
 Neural cells (ganglion cells, bipolar neurons and amacrine cells): The ganglion 
cells (GC) are the output neurons. Its axons constitute the optic nerve and 
transmit the visual information from the retina to the brain. The bipolar cells 
(BC) are involved in the synaptic transmission from the photoreceptors to the 
ganglion cells. Amacrine cells (Am) are interneurons that affect the output from 
bipolar cells, interacting with ganglion cells (Naik et al., 2009, Hoon et al., 
2014). 
 Photoreceptors (cones and rods): Photoreceptors (PRs) are responsible for the 
conversion of light energy through changes in the membrane potential that 
alters neurotransmitter release. There are two classes of PR, rods and cones. 
Rods are responsible for the low-light vision and are located throughout the 
peripheral retina. By contrast, cones are located at the central part of the retina 
(macula) and are responsible for the central and color vision (Colthurst et al., 
2000, Naik et al., 2009). 
 Retinal pigment epithelium (RPE): The RPE is located between the outer 
segments of the PR and the choroid. It is a monolayer composed by hexagonal 
cells connected by tight-junctions, containing pigment granules. The apical 
membrane faces the subretinal space and interacts with the outer segment of 
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the PRs. The basolateral membrane of the RPE is in contact with the Bruch 
membrane that is in direct contact with blood in fenestrated vessels of the 
choroid (Strauss, 1995). Figure 1.3 outlines some of the RPE functions.  
 
Figure 1.3: The retinal pigment epithelium (RPE) and its main functions: light 
absorption, transepithelial transport, reisomeriztion of all-trans-retinal, phagocytosis 
and secretion of growth factors, such as Vascular Endothelial Growt Factor (VEGF) 
and neurotrophic factor, like Pigment Epithelium-Derived Factor (PEDF). Adapted from 
(Strauss, 2005). 
 
RPE is responsible for light absorption, transport of ions, water, and metabolic 
end products from the subretinal space to blood. RPE takes up nutrients, such 
as glucose, retinol, and fatty acids, essential for the maintenance of 
photoreceptors. Another important function of RPE cells is the reisomerization 
of all-trans-retinal into 11-cis-retinal, a key element of the visual cycle that is 
further transported back to photoreceptors to be incorporated in the visual cycle 
pathway. To ensure the excitability of PRs, RPE phagocytes and digests their 
shed outer segments, where recycling of retinal occurs to be returned and 
rebuild the outer segments of photoreceptors. Thus, the RPE needs to maintain 
the structural integrity of the retina by defending it efficiently from free radicals, 
photo-oxidative exposure and light energy. Furthermore, RPE produces and 
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secretes a wide range of growth and neurotrophic factors to support and 
maintain the structural basis of photoreceptors and choriocapillaris endothelium. 
A failure in any of these functions can induce retinal degeneration, loss of visual 
function, and irreversible blindness (Strauss, 2005, Simo et al., 2010). 
 
The eye is an attractive target for gene therapy. Due to its relative small size, it is 
only necessary a small amount of a drug to obtain a significant therapeutic effect. The 
eye also contains different cell types that can be specifically accessed by different 
delivery methods, enabling a targeted therapy when combined with the vector’s tropism 
(Bloquel et al., 2006). Moreover, its immune-privileged status due to the presence of 
the blood-retinal barrier (BRB) limits inflammatory reactions towards the vector (Bloquel 
et al., 2006, Farjo et al., 2010). Besides, therapy outcomes can be easily monitored by 
non-invasive methods, such as electroretinography (ERG) and optical coherence 
tomography (OCT), to complement patient input (Petrs-Silva et al., 2014). In particular, 
retinal disorders are good targets of ocular gene therapy because in most cases the 
genetic etiology is known and several animal models exist or have been generated to 
help design new therapeutic strategies. Moreover, PR and RPE cells, which are more 
often affected by these mutations, can be easily accessed by subretinal injection 
(Cheung et al., 2010). 
 
1.3. Retinal diseases 
Diseases affecting the retina are blinding disorders influenced by genetic and 
environmental factors, altogether contributing to more than 25% of blindness cases 
(Naik et al., 2009). 
The fact that current treatments for these diseases are ineffective makes them 
ideal candidates for gene therapy (Naik et al., 2009).  
Retinal disorders can be classified as inherited or acquired diseases. Most of 
inherited retinal diseases are caused by mutations in genes expressed in the PRs and 
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RPE cells. There are more than 200 identified genes responsible for these diseases 
(http://www.sph.yth.tmc.edu/RetNet/) (McClements et al., 2013). Examples of inherited 
retinal diseases are Leber Congenital Amaurosis (LCA), Choroideremia (CHM), 
Retinitis Pigmentosa (RP), among others. Acquired retinal disorders include, among 
others, Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) that 
results from a combination of aging, environmental, and genetic factors that damage 
the retina and RPE (Chaum et al., 2002). In the following sections a genetic and an 
acquired retinal disease will be used as examples of potential therapeutic approaches, 
mostly focused on gene therapy. 
 
1.3.1. Retinitis Pigmentosa 
Retinal degeneration is characterized as a deterioration of the retina, usually 
caused by a massive cell death. Retinitis Pigmentosa (RP) is one of the most common 
types of inherited retinal degeneration that can result from defects in more than 60 
genes, displaying all three types of Mendelian inheritance: autosomal dominant (30%-
40% of cases), autosomal recessive (50%-60%) or X-linked (5%-15%), but it can also 
occur in combination with other systemic disorders such as Usher syndrome, Refsum 
disease, Bassen-Kornzweig syndrome, Bardet-Biedl syndrome, and Batten disease. 
There are still 30%-35% of RP patients whose mutations cannot be identified (Shintani 
et al., 2009, Petrs-Silva et al., 2014).  
Despite the genetic heterogeneity of this disease, RP patients present several 
common features, such as pigment accumulation, dysfunction of PRs and/or RPE, 
massive loss of PRs, abnormal ERG, night blindness and loss of peripheral field vision 
(Petrs-Silva et al., 2014).  
To date there is no cure available for RP, however the effectiveness and safety of 
several potential treatments are being evaluated (Musarella et al., 2011). A brief 
description of each of these is presented below. 
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1.3.1.1. Vitamin Therapy 
Vitamin A may protect PRs through its trophic and antioxidant properties. Berson 
et al. have demonstrated a delay in PRs death after daily ingestion of 15000 IU of 
Vitamin A (Berson et al., 1993). More recently, the same group showed that the intake 
of Vitamin A can retard blindness up to 10 years (Berson, 2007). The administration of 
Vitamin A in combination with a diet rich in omega-3 fatty acids also show slight 
improvements (Musarella et al., 2011). 
Other studies showed a delay in the progression of the disease with the 
combination of Vitamin A with the antioxidant lutein (Berson et al., 2010). 
 
1.3.1.2. Retinal Implant 
Epiretinal and subretinal implants have been performed in animal models, showing 
that cortical activity can be induced. This is currently being tested in humans, but the 
long-term effect of the implants has yet to be evaluated, as well as the effect on the 
retinal function of the electrodes placed between the neuroretina and the RPE layer 
(Musarella et al., 2011). 
 
1.3.1.3. Stem cells and retinal transplantation 
Some studies showed an improvement in visual acuity and pupillary light response 
after the implant of fetal retina and PR precursors, respectively. The use of stem cells 
is advantageous because it is possible to prepare unlimited numbers of progenitor 
cells. The main disadvantages are the need to predict the ideal number of cells for 
engraftment and most of time the engrafted cells does not develop synaptic 
connections (Musarella et al., 2011) and the need of lifelong immunosuppressive 
therapy due to allograft transplantation (Li et al., 2012). The development of autografts 
from patient-specific induced pluripotent stem (iPS) cells has shown great potential to 
solve this problem and has been used as cell therapy in pre-clinical trials (Li et al., 
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2012), as well as an in vitro model to study the signaling pathways involved in the 
pathophysiology of the disease (Lukovic et al., 2015). 
 
1.3.2. Diabetic retinopathy 
Diabetes mellitus is a group of metabolic diseases characterized by high blood 
glucose that leads to several complications, including diabetic retinopathy (DR). With 
the increased survival of individuals with diabetes, DR remains the major cause of 
vision loss in developed countries, affecting mostly working-age adults, as it develops 
approximately 20 years after the onset of diabetes (Cheung et al., 2010). 
DR is classically regarded as a microvascular complication of diabetes that leads 
to the neovascularization within the retina (Cheung et al., 2010, Farjo et al., 2010). The 
pathophysiology underlying diabetic retinopathy is still unknown, but is believed that the 
chronic exposure to hyperglycemia and other risk factors, such as hypertension, 
triggers a cascade of biochemical and physiological changes that originate 
microvascular damage and retinal dysfunction (Cheung et al., 2010). Several 
biochemical mechanisms have been proposed to be responsible for the 
pathophysiology of the disease (Figure 1.4) including the accumulation of sorbitol and 
advanced glycation end-products (AGEs), reactive oxygen species (ROS) production, 
protein kinase C activation (PKC), inflammation, upregulation of the renin-angiotensin 
system (RAS) and of vascular endothelial growth factor (VEGF) (Frank, 1995, Antonetti 
et al., 2006, Cheung et al., 2010).  
Altogether, these biochemical mechanisms contribute to structural and 
physiological changes, including retinal capillary basement membrane thickening that 
induces pericyte and endothelial cell death, causing inner BRB (iBRB) breakdown. This 
loss of retinal capillary function leads to vascular wall leakage, inflammation, and 
ischemia, contributing to retinal neovascularization, formation of microaneurysms, 
edema, and hemorrhages leading to irreversible blindness  (Frank, 1995, Cheung et 
al., 2010).  
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Figure 1.4: Pathophysiology of diabetic retinopathy. Hyperglycemia and hypertension 
initiates a cascade of biochemical events that leads to microvascular damage and 
ultimately vision loss. Adapted from (Cheung et al., 2010). 
 
Retinal ischemia is an important component of the pathogenesis of retinal 
neovascularization. Ischemia induces cellular hypoxia that in turn is responsible for a 
broad-range of signaling pathways to overexpress angiogenic stimulators, such as 
VEGF, a potent pro-angiogenic factor. In a normal retina, RPE expresses a small 
amount of vascular endothelial growth factor (VEGF) and high levels of pigment 
epithelium-derived factor (PEDF), a potent anti-angiogenic molecule. Due to hypoxia 
during diabetes, the balance between pro- and anti-angiogenic molecules is disrupted, 
leading to up-regulation of VEGF and down-regulation of PEDF. As a consequence of 
this imbalance, there is promotion of neovascularization and subsequent vision loss 
(Farjo et al., 2010). 
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Regarding its progression, DR can be clinically classified as non-proliferative DR 
(NPDR), characterized by microaneurisms and damage in the retinal capillaries, and 
proliferative DR (PDR), which is recognizable by the presence of ischemia, 
neovascularization and hemorrhages, causing irreversible vision loss (Cheung et al., 
2010). 
At present, there is no effective treatment for DR. Tight glycemic control is the 
most efficient therapy to slow progression of DR. Blood pressure should also be taken 
in consideration since hypertension aggravates the disease by increasing blood flow, 
and causing mechanical damage to the vascular endothelial cells, thus stimulating the 
production of VEGF (Fong et al., 2004, Cheung et al., 2010).  
For advanced stages, more invasive strategies are clinically applied an attempt 
to block progression of the disease, such as laser photocoagulation, vitrectomy and 
anti-VEGF therapy. 
 
1.3.2.1. Laser photocoagulation 
Laser photocoagulation is the most widely used technique to treat proliferative DR. 
The aim of photocoagulation is to cause laser burns all-over the retina to help 
regression and slow progression of retinal neovascularization, by reducing ischemia 
induced by VEGF production. However, despite its efficiency preventing visual loss, the 
damaging nature of laser carries several ocular side-effects, including poor light-dark 
adaptation and decrease in visual acuity. Moreover, if the therapy is not started timely, 
halting of vision loss cannot be guaranteed (Cheung et al., 2010). 
 
1.3.2.2. Vitrectomy 
Vitrectomy is the most effective surgical treatment for complications of advanced 
retinopathy, such as vitreous hemorrhage and retinal detachment. However, despite its 
efficiency reducing the risk of retinal neovascularization development, it markedly 
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increases the risk of iris neovascularization and cataract formation (Cheung et al., 
2010). 
 
1.3.2.3. Anti-VEGF Therapy 
VEGF is an important mediator of angiogenesis and is the main responsible for 
abnormal neovascularization, leakage and BRB breakdown. Inhibition of VEGF may 
play an important role the DR prevention. Three VEGF antagonists have been 
assessed in clinical trials as anti-VEGF therapy: i) Pegaptanib, ii) Ranibizumab and iii) 
Bevacizumab. These agents are delivered by intravitreal injection, to ensure maximum 
local efficiency with minimal systemic side effects (Shah, 2008, Cheung et al., 2010).   
Pegaptanib (Macugen®) is a RNA aptamer that acts by binding VEGF165 isoform, 
the prevalent isoform in the human eye and principal responsible for normal and 
pathologic neovascularization. The binding of Pegaptanib to VEGF165 leads to its 
deactivation and ultimately inhibition of vascular permeability and neovascularization 
(Praidou et al., 2010). 
Ranibizumab (Lucentis®) is a humanized recombinant monoclonal antibody 
fragment that recognizes all known human VEGFA isoforms (i.e. VEGF121, VEGF145, 
VEGF165, VEGF189 and VEGF206) and possesses one antigen binding epitope (Shah, 
2008, Praidou et al., 2010). 
Similarly to Ranibizumab, Bevacizumab (Avastin®) is also a humanized 
recombinant monoclonal antibody that binds and blocks the action of all VEGF-A 
isoforms but displays two antigen binding epitopes (Shah, 2008, Praidou et al., 2010). 
Despite its efficacy inhibiting VEGF and reducing neovascularization and its 
complications, the major disadvantage of these drugs is its short half-life that varies 
from 3 days for Ranibizumab (Bakri et al., 2007), 10 days for Pagaptanib (Vinores, 
2006) and 21 days for Bevacizumab (Praidou et al., 2010), increasing the need of 
repeated injections and severe side-effects, such as cataract formation, retinal 
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detachment, vitreous hemorrhage, infection and loss of neural retinal cells (Cheung et 
al., 2010).  
Other strategies using VEGF receptor blockers and siRNA against VEGF mRNA 
have also being used in order to prevent the interaction of VEGF with its receptor, thus 
stopping the subsequent signaling pathway, and the production of VEGF protein 
(Praidou et al., 2010). However, these approaches still need recurrent administrations, 
halting the importance of an efficient and prolonged strategy to target VEGF. 
 
Regardless of the acquired or genetic nature of the disease, it is clear that 
conventional therapies are insufficient for retinal pathologies, either because they do 
not prevent the progression of the disease or because they treat the symptoms, not the 
cause. In this regard, gene therapy is a very promising approach to treat retinal 
pathologies, as shown by clinical trials for LCA (Maguire et al., 2009) and CHM 
(MacLaren et al., 2014). For RP, gene therapy currently represents the most promising 
strategy. AAVs are the most widely used vector for this purpose, due to tropism for 
retinal cells, lack of toxicity and absence of immune response, all features that will be 
later discussed (Petrs-Silva et al., 2014). In the autosomal dominant forms of RP 
(adRP) both normal and abnormal outer segment proteins are produced in the PRs but 
the abnormal form of the protein is toxic, causing progressive apoptosis of PRs. 
Because there are several mutations associated with adRP, targeted gene elimination 
or repair for each separate mutation is difficult to achieve. An alternative would be to 
stimulate cell survival, by the use of growth factors, and anti-apoptotic therapies to 
delay the progression of the disease (Chaum et al., 2002, Petrs-Silva et al., 2014). 
In autosomal recessive RP (arRP), the patient has two mutated copies of the gene. 
In this cases gene replacement of the mutated copies by the correct gene is the most 
effective strategy (Chaum et al., 2002). X-linked RP is the most severe form of the 
disease and similarly to arRP, gene replacement is the most viable approach (Chaum 
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et al., 2002, Petrs-Silva et al., 2014). However, for neither two forms exist yet a 
proposed gene therapy approach under trial. 
For diabetic retinopathy, there are gene therapy strategies being studied (Igarashi 
et al., 2003, Zhang et al., 2015) that have yet to reach clinical trials. This is caused by 
the fact that the etiology is still not fully elucidated. 
For a gene therapy strategy to be successful in treating retinal diseases, it needs 
to reach the therapeutic target, and for that, it needs to overcome several barriers. 
 
1.4. Barriers to Gene Therapy 
Gene delivery is considered the most challenging issue in gene therapy, as the 
delivery vector needs to overcome a series of extra and intracellular barriers. The next 
section focuses on these barriers that are common to all administration routes. 
 
1.4.1. Extracellular barriers  
Regardless of the route by which the vector is administered, it will interact with a 
wide-range of different molecules. Vectors administrated intravenously can easily suffer 
degradation by endo- and exo-nucleases present in the serum. The serum itself is 
composed by several proteins that can bind to vectors, resulting in aggregation, 
degradation and removal from the circulation by the reticuloendothelial system, 
affecting the stability and bioavailability of the vectors. The administration of vectors 
can also stimulate the immune system resulting in inflammation and complement 
activation, contributing for the clearance of the vectors (Gottfried et al., 2013). 
 
1.4.2. Extracellular barriers in the eye 
Gene delivery through intravenous administration is often associated with reduced 
bioavailability due to removal from blood circulation. Apart from the blood circulation, 
retinal gene therapy needs to overcome various barriers present at the anterior and 
posterior segments of the eye that restrict the entry of naked DNA, or viral and non-
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viral vectors, such as the blood-aqueous barrier, the blood-retinal barrier, the corneal 
barrier, and the vitreal barrier (Figure 1.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Scheme of the human eye, showing the main barriers for retinal gene 
delivery. The blood-aqueous barrier and blood-retinal barrier represent an obstacle to 
intravenous and subretinal injection. Corneal barrier is a barrier to topic administration 
and vitreal barrier represents a barrier after intravitreous injection. Adapted from (Naik 
et al., 2009). 
 
Blood-Aqueous Barrier (BAB) 
The BAB is responsible for the nutrition of the cornea and lens, and its main 
components are the ciliary body and the iris. BAB regulates nonspecific entry of 
potential dangerous substances from systemic circulation to the aqueous humor. 
However, the BAB is less powerful than the blood-retinal barrier (Chen et al., 2008, 
Tamboli et al., 2011). 
 
Blood-Retinal Barrier (BRB) 
The BRB is responsible for the homeostasis of the neuroretina and is divided into: 
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i) the inner BRB (iBRB) – formed by tight junctions between endothelial cells of 
the retinal vessels. This barrier allows the transport of small molecules such as 
glucose, by facilitated diffusion, while preventing widespread diffusion of 
substances into the retina (Cunha-Vaz, 1979, Farjo et al., 2010, Gottfried et al., 
2013);  
ii) the outer BRB (oBRB) – formed by intracellular tight junctions in the RPE 
monolayer. This barrier allows bidirectional flow of essential metabolites, such 
as glucose, through the Na+/K+-ATPase pump, but restricts the passage of more 
complex molecules from the choroidal blood supply into the neural retina 
(Cunha-Vaz, 1979, Farjo et al., 2010, Gottfried et al., 2013). 
 
Corneal barrier 
An alternative to intravenous administration would be topical administration. 
However, this is not an effective way for retinal gene delivery since it comprises 
penetration of the cornea and diffusion from the vitreous to the retina, against the 
natural flow of the aqueous humour. 
The cornea consists of five to seven layers, in which the outermost one is 
composed of six to seven layers of stratified epithelium connected by tight junctions, 
which act as a barrier for vectors entry, limiting the amount of vector that reaches the 
retina. Moreover, a great portion of the vehicle is returned to the systemic blood 
circulation through the conjunctival and nasal blood vessels (Naik et al., 2009, Tamboli 
et al., 2011) 
 
Vitreal barrier 
In order to overcome these barriers, administration can be local. This is achieved 
by subretinal and intravitreal injections, which have become the most common 
administration procedures for in vivo retinal gene delivery.  
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Direct injection in the subretinal space, between the retina and choroid, increases 
contact between the vector and the retinal layers; the contact area is however 
restricted to the injection site. Additionally, this type of injection can induce lesions in 
RPE cells and is technically challenging, restricting its clinical application.  
Intravitreal injection is more acceptable for clinical applications, because it is a less 
invasive technique. But it is not as effective as subretinal injection, since the vectors 
can still be cleared by fluid flow, thus needing repeated intraocular administration to 
achieve therapeutic levels in the retina, which might lead to lens injury and retinal 
detachment. Moreover, the passage through the vitreous itself represents a barrier due 
to its gel-like three-dimensional net of collagen, proteoglycans, glycosaminoglycans 
(GAG) and serum components that are known to interact with nonviral vectors by 
immobilizing them in the proteoglycan mesh, binding to negative-charged GAG, 
causing its aggregation and blocking cellular uptake and/or intracellular trafficking (Naik 
et al., 2009).  
 
1.4.3. Intracellular barriers of gene delivery 
The vectors that overcome the extracellular barriers and reach the target cells 
need to be internalized in order to ensure the genetic material is directed to the 
nucleus. In Figure 1.6 the intracellular barriers are represented: cellular membrane, 
endocytic trafficking, cytoplasmic transport, nuclear penetration, and gene expression.  
The cellular membrane represents the first barrier for the vectors. DNA is an 
anionic molecule and cannot cross the also negatively-charged cell membrane. The 
use of positively-charged carriers can minimize this problem by neutralizing the 
negative charge of DNA, thus promoting cellular uptake by receptor-mediated 
endocytosis or non-specific endocytosis (Wiethoff et al., 2003, Wong et al., 2007). 
Once inside the cell, the endocytic vesicles containing the vectors can be recycled 
back to the cell surface, converted into acidic vesicles (such as lysosome and 
phagosome), or delivered to an intracellular organelle (such as Golgi apparatus or 
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endoplasmic reticulum), depending on the internalization path. There are several 
proposed mechanisms by which the vectors can perform the endosomal escape, 
including membrane fusion, the proton-sponge effect, and integration of fusogenic 
peptides (Wong et al., 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Cellular barriers to gene transfer: DNA protected by a cationic nanoparticle 
enters into the cell by endocytosis (1). Inside the cell, the DNA/nanoparticle complex 
should escape lysosomal degradation (2), cross the cytoplasm (3) and the nuclear 
envelope (4) and finally access to the cellular transcription machinery (5). Adapted from 
(Wong et al., 2007). 
 
Vectors based on cationic lipids are able to escape the endosome through fusion 
with the endosome membrane. In contrast, cationic polymers accomplish endosomal 
escape through a proton-sponge mechanism. The proton-sponge effect is based on the 
protonation of the amine groups of the cationic polymers, leading to an accumulation of 
protons. This accumulation causes influx of chloride ions that induces water entry, 
resulting ultimately in endosome swelling and rupture (Gottfried et al., 2013). 
After the DNA is successfully released, it must be directed to the nucleus. The 
cytosol represents another significant barrier to gene delivery. It has been postulated 
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that only 1-10% of the transfected plasmid reaches the nucleus (Gottfried et al., 2013). 
This is due to the presence of nucleases in the cytosolic milieu that can degrade the 
naked DNA and the mechanical resistance exerted by the cytoskeleton network that 
impedes the diffusion of the unprotected DNA to the nucleus (Wiethoff et al., 2003, 
Wong et al., 2007). However, it is believed that several vectors interact with the 
cytoskeleton proteins to reach the nuclear envelope (Wiethoff et al., 2003, Vaughan et 
al., 2006). 
There are at least three possible pathways for nucleic acids to enter the nucleus. 
The simplest way is during mitosis, when there is disruption of the nuclear envelop. If 
smaller enough, nucleic acids can also cross the nuclear membrane through nuclear 
pore complexes by facilitated diffusion or it could transverse the nuclear envelope by 
simple diffusion. DNA transport through nuclear pores can be even facilitated by 
incorporation of specific sequences recognized by nuclear pore complexes, called 
nuclear localization signals (NLS) (Wiethoff et al., 2003, Gottfried et al., 2013). 
Gene therapy can constitute an efficient therapeutic strategy for the retinal 
pathologies described previously. In order to develop such a therapy, several points 
need to be taken into consideration, such as the delivery vector and gene expression 
system. These will be dealt with in greater detail in the following sections of this 
chapter. 
 
1.5. Gene Delivery Systems 
For overcoming the barriers mentioned in section 1.4 of this chapter and guarantee 
the success of gene therapy, the gene of interest should be efficiently delivered to the 
target cells. Since naked DNA is not usually internalized by the cells due to their 
hydrophilic nature, large size and negative charge (conferred by the phosphate 
groups), delivery systems have been developed to guarantee efficient gene transfer 
(Cevher et al., 2012). 
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Gene delivery systems can be categorized in two major groups: viral and non-viral. 
Non-viral methods can be further divided into physical and chemical delivery methods 
(Chaum et al., 2002, Cevher et al., 2012).  
Each method was developed and optimized to achieve therapeutic gene 
expression levels based on the nature of the gene to be delivered, target cells and 
route of administration (Chaum et al., 2002). Both viral and non-viral vectors currently 
used possess not all characteristics of an ideal vector. Their characteristics, 
advantages and disadvantages for retinal use will be discussed in this section. 
 
1.5.1. Viral-based Gene Delivery Systems 
Viral vectors represent currently more than 50% of the gene therapy vehicles used 
in clinical trials (Figure 1.7) (Gascón et al., 2013). In the retina, the most widely used 
viral vectors are Adenovirus (Ad), Adeno-Associated virus (AAV), Retrovirus, 
Lentivirus, and Herpes Simplex virus (HSV) (Chaum et al., 2002, Cevher et al., 2012). 
. 
 
 
 
 
 
 
 
 
Figure 1.7: Gene delivery systems used in clinical trials. The use of naked/ plasmid 
DNA is one of the most widely used gene delivery systems, preceded only by 
Adenoviruses and Retroviruses. Adapted from (Gascón et al., 2013). 
 
The main advantage of viruses as gene vectors is their natural capacity to 
transduce cells, efficiently delivering their cargo into host cells, originating high levels of 
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gene expression (Atkinson et al., 2010, Cevher et al., 2012). Moreover, some viruses 
display cellular tropism, such as HSV for neuronal cells (Chaum et al., 2002) and some 
AAV serotypes for retinal cells (Rabinowitz et al., 2002), allowing for a targeted 
therapy. Disadvantages associated with viral vectors are their immunogenicity, toxicity, 
tumorigenicity, limited packaging capacity, and difficulties in large-scale production 
(Naik et al., 2009, Cevher et al., 2012) 
 
1.5.1.1. Adenoviruses  
Adenoviruses are well characterized, non-enveloped, non-integrative, and linear 
double stranded DNA (dsDNA) viruses that are able to transduce a huge variety of 
human and non-human cells by binding to specific receptors, such as Coxsackievirus 
and Adenovirus Receptor (CAR) and Toll-Like Receptor-4 (TLR4) (Chaum et al., 2002, 
Cevher et al., 2012). In the retina, Adenovirus vectors have been efficiently used to 
transduce PR (Anglade et al., 1998, Bennett et al., 1998, Von Seggern et al., 2003), 
GC (Bennett et al., 1994, Cayouette et al., 1997), Müller cells (Di Polo et al., 1998, 
Fukuhara et al., 1998, Zhou et al., 2014) and RPE cells (da Cruz et al., 1996, da Cruz 
et al., 1998, Lam et al., 2014). 
These viruses are capable of incorporating DNA fragments up to 36 kb (Cevher et 
al., 2012) but it remains as an episomal particle (since it is not integrated into the cell 
genome), being eventually silenced or lost, with gene expression decaying in few 
weeks (Bennett et al., 1994, Jomary et al., 1994). Repeated administrations lead to the 
most serious problem associated in using Adenovirus vectors: the strong immune and 
inflammatory response that hampers gene expression (Chaum et al., 2002, Cevher et 
al., 2012).  
 
1.5.1.2. Adeno-Associated Virus 
Adeno-Associated Virus (AAV) vectors are non-enveloped, single stranded DNA 
(ssDNA) viruses that, similarly to Adenovirus, are able to infect both mitotic and post-
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mitotic cells persisting as an episomal particle, without integration into host cell 
genome. However, the presence of the rep protein in 10% of transduction events 
enables AAVs to integrate into host genome in a specific locus of chromosome 19, 
allowing a stable transgene expression and, simultaneously decreasing the possibility 
of random insertional mutagenesis (Kay et al., 2001). The main disadvantage of using 
AAV is however its limited packaging capacity of 5 kb (Chaum et al., 2002).  
In the retina, AAVs have found widespread use, being used to transduce PR, GC 
and RPE cells and are currently being used in more than one clinical trial for congenital 
blindness (Bainbridge et al., 2008, Hauswirth et al., 2008, Maguire et al., 2009, 
MacLaren et al., 2014). 
 
1.5.1.3. Retroviral vectors  
Retroviruses are a family of diploid ssRNA that have the ability to infect and 
randomly integrate its genome into the host cells’ genome to produce new viral 
particles, being associated with insertional mutagenesis and tumor formation (Kay et 
al., 2001, Chaum et al., 2002, Cevher et al., 2012). The possibility of generating wild-
type (WT) HIV virus during titer production or by viral recombination are also 
disadvantages of these vectors (Chaum et al., 2002).  
The retroviral family is divided into gammaretrovirus and lentivirus, which differ in 
their capacity to infect only post-mitotic or any cell, respectively. 
Retroviral and lentiviral vectors can both pack up to 8 kb of exogenous DNA, but 
retroviral vectors require cell division to transduce the host cell. Since most retinal cells 
are post-mitotic, these vectors are not considered the ideal vector for retinal gene 
therapy, where most of the cells are post-mitotic (Kay et al., 2001, Chaum et al., 2002, 
Cevher et al., 2012). 
Unlike retrovirus, lentiviruses can infect post-mitotic cells. Depending on the 
proteins present in the viral envelope, it is possible to construct “pseudo-typed” 
lentivirus to obtain a targeted gene transfer (Chaum et al., 2002, Cevher et al., 2012, 
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Nayerossadat et al., 2012). These pseudo-typed lentiviruses have been used to 
transduce a broad range of retinal cells (Miyoshi et al., 1997, Bainbridge et al., 2001, 
Bemelmans et al., 2005). 
 
1.5.1.4. Herpes Simplex Virus  
Herpes Simplex Viruses (HSV) are DNA virus with a natural tropism for neuronal 
cells, representing a great advantage for gene therapy of diseases affecting the 
nervous system, including the retina (Nayerossadat et al., 2012). Besides neurons, 
HSV virus is also able to infect other cell types and does not need nuclear envelope 
disruption to reach the nucleus, where its DNA recircularizes and is maintained as an 
episome (Chaum et al., 2002). 
This viral class is the one with the highest packaging capacity, being able to carry 
up to 150 kb of transgenic DNA (Nayerossadat et al., 2012). 
However, infection with HSV is usually associated with inflammation, cytotoxicity 
and cell death. For this, it has been mostly used for suicide gene therapy (Chaum et 
al., 2002). 
 
1.5.2. Non-viral Gene Delivery 
Despite the advantages in terms of transduction efficiency and gene expression, 
safety issues of viral vectors led the continuous search and development of alternative 
delivery systems. Non-viral vectors emerge as an alternative to viral vectors, due the 
lack of specific immune response, no limitation in transgene size, ease of large-scale 
and low cost of production (Niidome et al., 2002, Nayerossadat et al., 2012). However, 
the major limitation of using non-viral systems is the low transfection efficiency, 
precluding transgene expression at therapeutic levels (Cevher et al., 2012, 
Nayerossadat et al., 2012). 
Non-viral gene therapy can be classified as physical and chemical depending on 
how the transgene is delivered.  
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1.5.2.1. Physical methods for gene delivery 
The most basic form of gene therapy is the administration of naked DNA. 
However, it is easily degraded by nucleases in the serum and cleared by the 
monocytes and macrophages. Moreover, naked DNA alone is not able to cross the cell 
membrane, resulting in low expression and limited transfected area. The use of 
physical delivery methods can increase the transfection efficiency of naked DNA 
(Niidome et al., 2002, Cevher et al., 2012). 
Gene delivery using physical methods takes advantage of a physical force to 
disturb the cell membrane allowing intracellular gene transfer (Cevher et al., 2012, 
Ramamoorth et al., 2015). These methods include needle injection, gene gun, 
electroporation, sonoporation, photoporation, magnetofection, and hydroporation 
(Figure 1.8) (Gascón et al., 2013). 
 
Needle injection 
DNA is locally administered using a needle system. This technique has been used 
to transfect tissues such as muscle, skin, liver, cardiac muscle and tumours but the 
efficiency of needle injection is limited to the injection area and the DNA is often 
degraded by the mononuclear phagocytic system (Gascón et al., 2013, Ramamoorth et 
al., 2015). 
 
Gene gun 
Gene gun is an alternative to DNA injection, developed for gene delivery to plant 
cells, which possess a cell wall. In gene gun procedures, DNA-coated gold, silver or 
tungsten particles are accelerated to high speed to penetrate the target cells of the 
tissues, skipping the endocytosis step and lisossomal degradation. This technique 
allows the administration of precise amounts of DNA. The main disadvantages of this 
method are high cost of the system, the transient, and low gene expression and the 
superficial penetration of the DNA into the tissue, only transfecting cells at the surface 
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(Niidome et al., 2002, Nayerossadat et al., 2012, Gascón et al., 2013, Ramamoorth et 
al., 2015). 
 
 
 
 
 
 
 
 
 
 
Figure 1.8: Overview of physical methods for gene delivery. Adapted from (Niidome et 
al., 2002). 
 
Electroporation 
Electroporation is used to enhance gene uptake after local naked DNA injection. It 
acts by generating a transient permeability on the cell membrane through electric 
pulses that create pores. Pore formation occurs in approximately 10 nanoseconds and 
their size is estimated to be smaller than 10 nm in diameter. Small molecules such as 
nucleic acids can pass through these pores and travel from the cytoplasm towards the 
nucleus (Niidome et al., 2002, Ramamoorth et al., 2015). 
In vivo, electroporation has been extensively used for skin (Denet et al., 2004), 
muscle (Schertzer et al., 2008), lung (Zhou et al., 2008), corneal (Zhou et al., 2007) 
and retinal gene therapy (Matsuda et al., 2004, de Melo et al., 2011), as well as 
vaccination (Sardesai et al., 2011) and tumor treatment (Al-Sakere et al., 2007).  
Electroporation is a reliable and efficient non-viral method for gene delivery, 
showing transfection levels comparable to viral vectors (Cevher et al., 2012, 
Ramamoorth et al., 2015). The drawbacks associated with this method rely on the 
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depth of penetration of the electric pulse and potential tissue damage associated with 
the technical procedure, as well as some discomfort to the patient (Nayerossadat et al., 
2012). 
 
Sonoporation  
In sonoporation, ultrasounds are used to permeabilize the cell membrane for DNA 
uptake in a non-invasive and site-specific way (Gascón et al., 2013). 
The transfection efficiency of sonoporation is dependent on the frequency, time of 
treatment, size, and concentration of DNA, but it has been reported a 10-fold increase 
in gene expression after ultrasound irradiation, compared with naked DNA. The 
transfection efficiency can even be improved by the combination of ultrasounds with 
microbubbles. This system is usually used in brain, cornea, kidney, skeletal and heart 
muscle (Niidome et al., 2002, Cevher et al., 2012, Gascón et al., 2013). The major 
disadvantage of this technique is its low efficiency in vivo (Nayerossadat et al., 2012).  
 
Photoporation 
Photoporation uses a single laser pulse to generate transitory pores on the cell 
membrane, leading to DNA entry. The efficiency of the system is controlled by the size 
of the focal point and pulse frequency of the laser. The gene expression is described to 
be similar to that of electroporation but an in depth study on its efficiency has yet to be 
performed (Nayerossadat et al., 2012, Gascón et al., 2013). 
 
Magnetofection 
Gene transfer by magnetic force that uses a magnetic field to accomplish gene 
transfer. DNA is complexed with magnetic nanoparticles (NPs) of iron oxide and coated 
with cationic lipids or polymers. This technique produces a rapid and efficient 
transfection, even in cells that are known to be difficult to transfect by other means, 
such as primary cells (Nayerossadat et al., 2012, Gascón et al., 2013). In vivo, 
   Chapter 1 
29 
 
magnetofection has been used for gene and drug delivery to the brain, blood vessel 
endothelium, lung, liver and several carcinoma xenografts in mice (Plank et al., 2011).  
 
Hydroporation  
Also known as hydrodynamic gene transfer, hydroporation is a technique that uses 
hydrodynamic pressure of the injection to increase the permeability of the cell 
membrane. It allows the injection of a large amount of DNA in few seconds (Niidome et 
al., 2002). This technique is usually applied in tail vein injection of rodents and is very 
effective for liver cells transfection, due to direct entry of the DNA into the inferior vena 
cava that stretches the myocardial fibers, inducing cardiac congestion, and driving the 
injected DNA solution into the liver in retrograde (Suda et al., 2007). The disadvantage 
of this method is the high injection volume that can cause damage to the tissues 
(Nayerossadat et al., 2012, Gascón et al., 2013). 
 
1.5.2.2. Chemical methods of gene delivery 
For gene delivery, chemical methods are more commonly used than physical ones 
(Nayerossadat et al., 2012). Gene carriers can be designed to simultaneously i) protect 
the therapeutic gene from blood components and nucleases, ii) to target a specific cell 
type, iii) to increase the delivery of the DNA to the cytoplasm or to the nucleus, iv) to be 
able to dissociate from the DNA in the cytosol, and also v) to release the cargo in the 
tissue in a continuous and controlled way (Niidome et al., 2002). 
For these purposes, different chemical systems have been developed, such as 
inorganic particles, cationic lipid-based particles, polymer-based particles, and 
synthetic peptides. Among these, polymer- and lipid-based systems are the best 
studied and characterized (Nayerossadat et al., 2012, Ramamoorth et al., 2015) and 
will be briefly addressed in this section.  
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Inorganic particles 
Inorganic particles are nanostructures that can be obtained from metals (such as 
gold, silver and iron), inorganic salts, and ceramics (like calcium-phosphate and silica). 
Calcium phosphate nanoparticles were the first inorganic particles used for gene 
therapy (Ramamoorth et al., 2015). These particles have the advantage of being easily 
engineered in size, shape, porosity, and surface-functionalized to escape the 
reticuloendothelial system and to protect the genetic material from degradation or 
denaturation (Gascón et al., 2013). 
 
Cationic Lipids 
Cationic lipids are amphiphilic molecules containing a hydrophilic positive-charged 
head and a hydrophobic tail. They promote DNA complexation by electrostatic 
interactions between the negative charge of DNA (conferred by the phosphate groups) 
and the positive charge of the positive head (that are usually amine groups). The 
complexation of a positive-charged lipid with the negative-charged DNA is 
denominated lipoplex, in which DNA is encircled by the positive lipid (Gascón et al., 
2013, Ramamoorth et al., 2015). 
The transfection efficiency of the lipoplex depends on the shape, number of 
charged groups per molecule, and the charge ratio to produce the lipoplexes. Due to its 
positive charge, lipoplexes can interact electrostatically with negative-charged proteins 
and proteoglycans present in the membrane of the cells, thus promoting the uptake of 
the complex. The complex is then internalized into the cell by the vesicular path, 
followed by the release of DNA from the lipoplex into the cytosol that hopefully will 
reach the nucleus to be transcribed and translated into a therapeutic protein (Cevher et 
al., 2012).  
The limitations of using these molecules for gene therapy are the structural 
instability of the lipoplexes, aggregation, low transfection efficiency, poor targeting 
ability, toxicity, and fast clearance from the circulation.  Some strategies have been 
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used to avoid some of this disadvantages caused by the excessive charge-charge 
interaction (Cevher et al., 2012, Gascón et al., 2013, Ramamoorth et al., 2015). These 
include combination of the neutral polymer polyethylene glycol (PEG) that acts like a 
shield from the immune system, prolonging the half-life of the circulating lipoplexes 
(Gascón et al., 2013). 
 
Cationic polymers 
Polymers are long-chain structures composed by small repeating molecules, 
named monomers. Polymers composed by the same monomer are denominated 
homopolymers and polymers composed by different monomers are called copolymers 
(Cevher et al., 2012). 
According to its origin, polymers can be classified as natural or synthetic polymers. 
Regarding the mechanism of release, polymers can either be classified as degradable 
or non-degradable. Biodegradable polymers (such as chitosan, starch, polyamides, 
and dextran, among others) suffer chemical or physical reactions in biological 
environments, leading to chain shortening. In contrast, non-biodegradable polymers 
(like PEG, Polyethylenimine (PEI), and Poly(2-(dimethylamino)ethylmethacrylate) 
(pDMAEMA)) are not metabolized in biological environments, and therefore remain 
unchanged (Cevher et al., 2012, Ramamoorth et al., 2015). 
For the success of gene transfer, the polymer-based delivery system must protect 
the negative-charged DNA backbone from repulsion from anionic cell surface, 
condense the DNA as much as possible to facilitate endocytosis and phagocytosis, and 
should also protect DNA from nuclease degradation (Niidome et al., 2002, Cevher et 
al., 2012). While attempting to improve the performance of those systems, a direct 
relationship between the length of the polymer, gene transfer efficiency, and toxicity 
was found: as the length of the polymer increases, the transfection efficiency 
increases, but so does toxicity (Cevher et al., 2012). 
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It has recently been shown that these systems can be used as gene delivery 
systems for ocular gene delivery. No toxic effects due to the particles were observed 
and the retinal structure and function was maintained. The well-tolerated nature of 
these polyplexes suggests they are promising candidates for gene transfer to the retina 
and RPE (de la Fuente et al., 2008, Han et al., 2012). The only obstacle remaining to 
be overcome is the relative low transfection efficiency and transient gene expression, 
due to epigenetic silencing of the expression vector (Bloquel et al., 2006). On the 
former, there are several groups working towards optimized delivery vectors. The latter 
will be addressed later in this chapter.  
 
Peptide-mediated gene transfer 
Cationic peptides, such as lysine and arginine have also been widely used for 
gene therapy and some studies showed they can even be more efficient that 
polyplexes and lypoplexes in protecting the cargo, targeting cell-specific receptors, 
disrupting endosomal membrane and delivering the genetic material.  They can also be 
used to functionalize polyplexes and lypoplexes enabling a targeted therapy or 
promoting the transport of genetic material into the nucleus, known as nuclear 
localization signal (NLS) peptides. (Niidome et al., 2002, Ramamoorth et al., 2015). 
Despite all the advantages, the use of synthetic peptides for gene delivery is limited by 
high cost production and purification. Moreover there are no studies showing the ability 
of these systems to deliver large genes.  
 
1.6. Optimization of expression vectors for long-term gene therapy 
Besides the gene carrier, another factor that has to be taken into account for the 
success of gene therapy is the long-term and sustained transgene expression.  
Plasmids are widely used as expression vectors for non-viral gene therapy. They 
are easy to construct and allow large-scale propagation. Since its genomic integration 
is negligible, they display an excellent safety profile. More importantly, plasmids have a 
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virtual unlimited packaging capacity and can accommodate large fragments of DNA 
(Williams et al., 2011). 
A plasmid is a circular dsDNA molecule that can be found in almost all bacteria 
and is usually responsible for antibiotic resistance (Williams et al., 2011). Two distinct 
parts compose plasmid DNA (pDNA): i) the transcription cassette, and ii) the bacterial 
backbone (Figure 1.9). 
 
 
 
 
 
 
 
Figure 1.9: pDNA for gene therapy and its main components: origin of replication (Ori), 
promoter, transgene, polyA tail and antibiotic resistance gene. Adapted from 
(Mayrhofer et al., 2009). 
 
The transcription cassette carries the target gene and its regulatory elements, like 
the promoter and enhancers. The bacterial backbone contains all the machinery 
required for bacterial propagation, such as origin of replication (Ori) and antibiotic 
resistance gene (Mayrhofer et al., 2009).  
The effectiveness of gene therapy is compromised by the transient expression of 
genes due to pDNA loss during mitosis and gene silencing by epigenetic silencing 
events (Yew et al., 2002, Jackson et al., 2006, Hyde et al., 2008, Gill et al., 2009). The 
mechanism by which pDNA vectors are often silenced is still not fully understood. 
However, several studies point to immunostimulatory properties of pDNA, in particular 
its bacterial backbone. Bacterial DNA contains a high percentage of unmethylated CpG 
motifs responsible for the activation of innate immune response. The recognition of 
these unmethylated motifs by the mammalian host leads an inflammatory response, 
General Introduction 
34 
 
including activation of B cells, monocytes, macrophages, dendritic cells and natural 
killer cells. This contrasts with eukaryotic cells, where the CpG content is much lower 
and these islands are usually methylated. Therefore, the removal of bacterial elements 
can improve the safety and efficiency of pDNA for gene therapy (Mayrhofer et al., 
2009), and this led to the development of minicircles, MIDGE, and pFAR expression 
vectors, which will be further described. 
 
1.6.1. Minicircle: a plasmid devoid of bacterial backbone 
Minicircle DNA (mcDNA) is a supercoiled recombinant DNA molecule that only 
contains the expression cassette with the promoter, the transgene and the polyA tail 
(Mayrhofer et al., 2009). Minicircles were firstly described in 1997 by Darquet et al 
(Darquet et al., 1997) and have since been extensively used as vector for gene therapy 
(Darquet et al., 1999, Chen et al., 2003, Vaysse et al., 2006, Wu et al., 2006, 
Schuttrumpf et al., 2008, Zhang et al., 2008, Huang et al., 2009, Stenler et al., 2009, 
Yoon et al., 2009, Jia et al., 2010, Osborn et al., 2011, Viecelli et al., 2014). In all 
studies, minicircles displayed greater and longer transgene expression than the 
parental plasmid. 
mcDNA is originated from recombination of parental plasmid (PP). Conversion of 
PP into mcDNA is a complex process that implies an external stimulus to induce 
bacteria to express the genes encoding the recombination machinery, followed by the 
recombination step (Gaspar et al., 2015). The expression cassette present in the PP is 
flanked by two recombinase recognition sequences that after recombination originate 
two supercoiled DNA molecules derived from PP: i) a mcDNA molecule, containing the 
therapeutic expression cassette and ii) a miniplasmid (MP) containing the undesired 
bacterial backbone (Figure 1.10) (Mayrhofer et al., 2009). 
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Figure 1.10: Minicircle production: after the recombination process, the parental 
plasmid originates a mcDNA molecule and a miniplasmid (MP) molecule. Adapted from 
(Mayrhofer et al., 2009). 
 
The yield of mcDNA is highly affected by the recombination step that, ideally, 
should convert 100% of the PP to mcDNA molecules. However, this is not observed 
and the contamination of the mcDNA preparation with PP and MP vectors is very 
inconvenient from a therapeutic point of view. Therefore, after recombination a 
purification step is required to eliminate the remaining PP and the MP originated from 
the recombination, thus isolating the mcDNA molecules. Different integrases have 
been used to increase the effectiveness of the recombination process, such as Phage 
λ integrase, Phage P1 Cre recombinase, ParA resolvase and PhiC31-integrase/I-SceI 
homing endonuclease system (Mayrhofer et al., 2009, Gaspar et al., 2015). 
 
1.6.1.1. Phage λ Integrase 
Phage λ integrase is a tyrosine recombinase that catalyzes conservative 
recombination. Its natural function is to perform integration of the λ phage into host cell 
genome (Gaspar et al., 2015). 
In the mcDNA production context, λ integrase was firstly used by Darquet et al. in 
where the recombinase was expressed endogenously by the bacteria, with the PP 
containing the hybrid attP/attB inserts flanking transcription cassette (Darquet et al., 
1997, Gaspar et al., 2015). 
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The major disadvantage of this system was the low yield of PP converted to 
mcDNA (40-70% recombination) due to the intrinsic toxicity of the λ integrase system. 
Therefore, the final mcDNA preparation was significantly contaminated with the PP 
template (Gaspar et al., 2015). 
 
1.6.1.2. Phage P1 Cre Recombinase 
Phage P1 Cre recombinase promotes bidirectional and site-specific recombination 
while it binds to its loxP recombination sites (Mayrhofer et al., 2009, Gaspar et al., 
2015).  
Its major disadvantage lies on the bidirectional and reversible recombination that 
can lead to the production of unwanted PP, MP, and concatamers (Mayrhofer et al., 
2009, Gaspar et al., 2015). This can be avoided by adding a mutated recombination 
site ensuring a unidirectional recombination (Gaspar et al., 2015).  
Even after this improvement, the conversion yield is not 100% and PP and MP are 
still present. An additional purification step was developed involving restriction 
endonuclease digestion of PP and MP after recombination and (CsCl)-ethidium 
bromide density centrifugation. However, due to its high cost, low yield, and poor 
scalability for pharmaceutical applications, this option was discarded (Gaspar et al., 
2015). 
 
1.6.1.3. ParA Resolvase 
ParA is a serine recombinase that catalyzes a unidirectional, conservative, site-
specific intramolecular recombination by binding to a target sequence containing two 
identical hybrid binding sites. With this system, no concatemerization was observed 
and the yield of recombination was about 99.5% (Gaspar et al., 2015). 
After recombination, the minicircle was purified using an affinity chromatography 
based on the recognition between LacO (present in the mcDNA) and its repressor LacI 
(present in the chromatography matrix). Only mcDNA containing these recognition sites 
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can bind to the matrix, making this system a promising platform for the large scale 
manufacture, and purification of clinical-grade mcDNA (Mayrhofer et al., 2009, Gaspar 
et al., 2015).  
 
1.6.1.4. PhiC31-integrase/I-SceI Homing System 
The bacteriophage ΦC31 integrase is a serine recombinase that promotes 
irreversible recombination between its attP/attB recombination sites, using catalytic and 
DNA-binding domains to control the procedure (Gaspar et al., 2015). 
With this system, the recombination sites in the PP are under tight control of the 
inducible pBAD/AraC protomer, allowing a conversion to mcDNA higher than 97% 
(Gaspar et al., 2015). The purification step is performed by co-expression of an 
endonuclease (I-SceI) that degrades both PP and MP remaining after recombination 
(Mayrhofer et al., 2009). 
 
Overall, mcDNA have shown great promise improving both expression levels and 
duration of expression. The elimination of the immunostimulatory CpG motifs present in 
the bacterial backbone together with its small size, known to facilitate the diffusion of 
the DNA through the cytoplasm and enhance its passage through the nuclear pores, 
seems to have a significant impact on mcDNA performance. However, further 
manipulation and monitoring of the process concerning the purification step is 
fundamental for clinical application (Gaspar et al., 2015).  
 
1.6.2. MIDGE vectors 
Minimalistic, Immunogenically Defined Gene Expression (MIDGE) vectors are 
linear molecules containing just the transcription unit (promoter, transgene and polyA 
tail) flanked by two hairpin oligonucleotide sequences, arranged in a covalently closed 
dumbbell-shaped molecule (Figure 1.11) (Schakowski et al., 2001, Machelska et al., 
2009).  
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These systems are obtained from the enzymatic digestion of a template plasmid 
and subsequent ligation of the resulting fragments to hairpin oligonucleotides. 
Afterwards, MIDGE vectors are purified by anionic exchange column chromatography 
(Schakowski et al., 2001, Machelska et al., 2009). MIDGE vectors have been used 
mostly for prophylactic genetic vaccination purposes (Moreno et al., 2004, Endmann et 
al., 2010). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11: MIDGE vectors production. MIDGE vectors are obtained from enzymatic 
digestion of the template plasmid following by hairpin oligonucleotide ligation. Adapted 
from (Machelska et al., 2009). 
 
Like mcDNA vectors, MIDGE vectors display several advantages over traditional 
plasmids such as their small size and low content in CpG motifs, due to the absence of 
bacterial backbone. Hairpin oligonucleotides present in MIDGE vectors can be 
functionalized by anchoring molecules such as peptides, proteins or sugars (Moreno et 
al., 2004). Examples of molecules that can be added are NLS peptides to target DNA 
to the nucleus (Machelska et al., 2009). 
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1.6.3. Plasmids Free of Antibiotic Resistance Gene (pFARs) 
Although mcDNA and MIDGE vectors lack antibiotic resistance gene, the PP is 
produced by dividing bacteria in the presence of antibiotics for selection. Besides 
unmethylated CpG motifs, the use of antibiotic resistance genes can contribute to the 
emergence of multidrug-resistance organisms, thus compromising the safety of the 
gene therapy (Marie et al., 2010). For that reason, plasmids free of antibiotic resistance 
genes (pFAR) were developed. There are several systems to replace antibiotic 
resistance gene, like auxotrophy complementation (AC), post-segregational killing 
(PSK) and operator-repressor titration (ORT) (Dong et al., 2010). 
The AC system uses an auxotrophic strain mutated for a crucial metabolite. In the 
absence of the specific metabolite, only strains having the plasmid encoding a tRNA 
allowing the translation of the metabolite can grow (Marie et al., 2010).  
The PSK system is dependent of the equilibrium between toxin and antitoxin 
encoded by genome and plasmid, respectively. If a cell loses the plasmid, the antitoxin 
will be degraded and the cell killed by the toxin encoded by its genome. However, this 
type of system is unable to maintain the plasmid during long-term bacterial culture 
(Dong et al., 2010).  
Finally, the OTR system uses plasmids with lac operator sequences that encode a 
repressor bound to an essential promoter or operator region (Marie et al., 2010). In 
case of plasmid loss, there is no expression of the repressor leading to bacteria death 
(Dong et al., 2010). 
 
1.6.4. Self-replicating episomal plasmids 
One of the major disadvantages of the non-viral gene therapy systems is their loss 
during mitosis, due to their inability to replicate in mammalian cells. Therefore, self-
replicating extrachromosomal systems represent several advantages over other non-
viral and also viral vectors.  
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Episomal vectors can be categorized in three general groups: i) self-replicating 
viral-based vectors, ii) chromosome-based vectors and iii) vectors containing S/MARs. 
 
1.6.4.1. Self-replicating viral-based vectors 
Epstein Barr virus (EBV) is a human herpes virus that can be maintained 
episomally in dividing cells. The maintenance is achieved by the expression of viral 
proteins, such as EBV nuclear antigen 1 (EBNA1) that allows the replication of the viral 
genome and its retention in the nucleus (Conese et al., 2004). 
Simian Vacuolating 40 (SV40) virus has the ability to replicate its genome 
episomally in eukaryotic cells through the interaction with the virally encoded trans-
acting factor large T-antigen (Piechaczek et al., 1999). 
Inclusion of these sequences in common plasmids allows them to replicate and be 
maintained in dividing cells. However, the presence of these viral elements can induce 
immortalization and tumor formation in transfected cells and have therefore reduced 
therapeutic usefulness (Piechaczek et al., 1999, Conese et al., 2004). 
 
1.6.4.2. Chromosome-based vectors 
Unlike self-replicating viral-based vectors previously described, chromosome-
based vectors do not require viral proteins for their functioning. They behave like 
natural chromosomes and are able to be stably maintained at a low and defined copy 
number in the cell in the absence of selection. The cloning capacity of these expression 
systems is infinite, allowing not only the insertion of the gene of interest but also 
promoters and all the elements required for a regulated and cell specific expression of 
the transgene (Lipps et al., 2003, Conese et al., 2004). The major drawback related 
with this system relates to the difficulty of finding a carrier to efficiently deliver such 
large artificial DNA chromosomes (Conese et al., 2004). 
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1.6.4.3. Episomal vectors containing S/MARs 
Scaffold/Matrix Attachment Regions (S/MARs) are AT-rich DNA sequences that 
anchor chromosomal loops to the nuclear matrix (Bode et al., 2000, Giannakopoulos et 
al., 2009). They are usually found at the borders of chromatin domains, either in non-
transcribed regions or within transcription units (close to promoters, enhancers and 
ORIs), but not in coding regions, suggesting they may act to link those regions to 
matrix-bound DNA/RNA enzymatic machineries (Bode et al., 2000, Giannakopoulos et 
al., 2009). 
S/MARs seem to be involved in DNA duplex destabilization and strand opening, 
suggesting an involvement in DNA replication and gene expression (Giannakopoulos et 
al., 2009), since the transition from the double stranded state to open stranded is 
required for replication and transcription (Giannakopoulos et al., 2009).  
Some viruses, such as the SV40 virus, contain S/MARs in their genome, which are 
part of the large T-antigen coding region. Without S/MARs, the virus is unable to 
maintain the episomal status for a prolonged period of time (Bode et al., 2000).  
Additionally, S/MARs-containing vectors are able to prevent epigenetic silencing by 
shielding the transgene sequence from adjacent regulatory sequences and 
heterochromatinization. This feature allows the maintenance of the vector in a 
transcriptional active state, conferring mitotic stability (Wong et al., 2011). S/MARs also 
mediates the association of the episome with the metaphase scaffold and facilitate the 
use of the centromere from the chromosome of host cells (Figure 1.12) (Bode et al., 
2000). 
 
 
 
 
 
 
 
 
 
Figure 1.12: Mechanism of retention of S/MAR-based vectors in mitotic cells. Adapted 
from (Lufino et al., 2007). 
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pEPI-1 was created by Piechaczek and coworkers and seems to be an alternative 
for gene transfer in mammals, allowing a stable maintenance in cells for about 100 
generations (Piechaczek et al., 1999). In pEPI-1, the gene coding for the SV40 T-
antigen was replaced by the S/MAR from the 5’-region of the human interferon β-gene 
(Piechaczek et al., 1999). The original pEPI-1 vector contains two mammalian 
transcription units and a total of 305 CpG motifs, most of them located in the elements 
of the vector required for bacterial propagation. In order to reduce the CpG content in 
the bacterial backbone of pEPI-1and achieve increased transgene expression in vitro 
and in vivo, a new S/MAR-based vector, named pEPito, was created (Haase et al., 
2010). pEPito was constructed by cloning the pEPI-1 plasmid replicon in a plasmid 
backbone lacking CpG motifs and excluding the second transcription unit  (Haase et 
al., 2010). Thus, pEPito contains only 37 CpG motifs (Haase et al., 2010). These 
plasmids, containing a CpG-rich transcription unit in a CpG-depleted bacterial 
backbone, seem to show similar expression patterns to minicircles and other CpG-free 
plasmids (Haase et al., 2010). Several other modifications have been made in order to 
try to improve S/MAR-containing plasmids, as depicted in table 1.  
The replacement of the CMV promoter by CAG promoter, hCMV/EF1 or tissue-
specific promoters were found to be crucial to avoid the epigenetic silencing of the 
promoter due to cytosine methylation (Hagedorn et al., 2012). Moreover, plasmids 
containing less CpG motifs in the backbone, such as pEPito vector, showed improved 
results compared with the original pEPI-1 vector (Haase et al., 2010). 
Likewise, minicircles containing S/MARs presented an increased and sustained 
expression, being maintained episomally with high establishment rates both in vitro and 
in vivo (Argyros et al., 2011). 
Additionally, plasmids containing S/MARs are currently being used to improve viral 
vectors, such as lentiviral vectors (Verghese et al., 2014) and adenoviral vectors 
(Voigtlander et al., 2013) in order to achieve a safe and efficient expression system for 
gene therapy. 
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Plasmid Backbone Promoter Transgene Expression 
Time 
Reference 
pEPI-1 pEPI-1 CMV eGFP 
2 months 
1 month 
(Piechaczek 
et al., 1999), 
(Papapetrou 
et al., 2006) 
pEPI-Luc pEPI-1 CMV Luciferase 6 months (Argyros et al., 
2008) 
pLucA1 pEPI-1 AAT Luciferase 6 months 
(Argyros et al., 
2008, Wong et 
al., 2011) 
pBcLucA1 pEPI-1 AAT Bcl2-
Luciferase 
3 months (Wong et al., 
2011) 
pEPito-CMV pEPito CMV eGFP 1 month (Haase et al., 
2010) 
pEPito-hCMV pEPito hCMV/EF1P eGFP 1 month 
(Haase et al., 
2010, Calado 
et al., 2014) 
pEPito-
hCMV/RPE65 
pEPito 
hCMV 
enhancer/ 
RPE65 
eGFP 1 month (Calado et al., 
2014) 
pUbC-Luc-
S/MAR 
pEPI-1 UbC Luciferase 5 months (Wong et al., 
2013) 
pUbC-FLCN-
S/MAR 
pEPI-1 UbC FLCN 5 months (Wong et al., 
2013) 
pEPI-TetON pEPI-1 TRE-Tight eGFP 2 months (Rupprecht et 
al., 2010) 
Mini-AAT-
S/MAR 
mcDNA AAT Luciferase 3 months (Argyros et al., 
2011) 
Mini-pUbC-
S/MAR 
mcDNA Ubc Luciferase 3 months (Argyros et al., 
2011) 
iBAC-S/MAR pEPI-1 CMV LDLR-eGFP 3 months (Lufino et al., 
2007) 
hβ-S/MAR pEPI-1 βLCR HBB 3 months (Sgourou et 
al., 2009) 
pEPI-b3a2 pEPI-1 hU6 bcr-abl 
shRNA 
4 months (Jenke et al., 
2005) 
pEPI-RNAi pEPI-1 hU6 HBV shRNA 8 months (Jenke et al., 
2008) 
VMD2-hRPE65-
S/MAR 
pEPI-1 VMD2 hRPE65 6 months (Koirala et al., 
2013) 
Table 1: Modifications of the original pEPI-1 applied to the promoter, backbone and 
transgene 
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As S/MARs-based vectors consist of extra-chromosomal elements, their episomal 
status gives an advantage over the safety risks associated with viral vectors. Moreover, 
their mitotic stability, long term expression, and high cloning capacity make them ideal 
systems for therapeutic purposes and future clinical applications. 
 
1.7. Specific Aims 
Despite the potential of non-viral vectors, their application in ocular gene therapy is 
still hindered by disadvantages such as low transfection efficiency and transient 
expression. Therefore, in this work we aimed to develop a multifactorial approach by 
combining long-term episomal expression systems, such as pEPitos with therapeutic 
genes and an efficient physical delivery method to enhance retinal gene therapy. With 
this combinatorial approach we intend to achieve expression of therapeutic levels of a 
gene of interest for a significant time period, therefore avoiding frequent administration 
and associated drawbacks. To achieve our goal we have divided our work-plan in three 
different tasks: 
i) Identify molecular targets of genetic and acquired retinal pathologies, such as 
Retinitis Pigmentosa (RP) and Diabetic Retinopathy (DR), respectively. 
ii) Test the efficacy of pEPito episomal vectors in long-term gene expression in 
retinal cells, both in vitro and in vivo. 
iii) Use the molecular targets identified in the first task combined with pEPito 
expression systems and test their ability of long-term gene expression and 
rescue of animal models of RP and DR, using electroporation to enhance 
transfection. 
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2.1. Abstract 
 
Ataxia telangiectasia and rad-3 (ATR) is a DNA damage response (DDR) enzyme 
that is usually associated with DNA damage checkpoint and cell cycle arrest. In 
humans, mutations in the ATR gene cause Seckel Syndrome, a rare disease 
characterized by intra-uterine growth retardation, microcephaly, facial and 
osteoskeletal abnormalities, as well as retinal degeneration. We have recently shown 
that the ATR protein is localized in the connecting cilium of photoreceptors (PR), and 
the mutant mice (ATR+/s) exhibit early-onset degeneration of rods and cones, and 
accumulation of pigment in the retina, suggesting a Retinitis Pigmentosa-like 
degeneration. To better understand the role of ATR in cilia formation and elongation, 
we decided to use an in vitro model of ciliated cells. Our hypothesis is that ATR 
inhibition should affect ciliary length. RPE-1 cells were cultured under serum-starvation 
conditions to induce primary cilia formation. ATR inhibition was performed by adding 
different concentrations of caffeine and ETP46464 to the culture medium. Our results 
show that under serum-starvation cultures, ATR is located in the base of the primary 
cilia and co-localizes with the centrosome of the ciliated cells. Moreover we found that 
ATR co-immunoprecipitates with γ-tubulin, a centrosome marker in the cells under 
serum-starvation conditions. After caffeine treatment, ATR expression decreases and 
this decrease is associated to a marked decrease in the cilia length, showing a direct 
effect of ATR in cilia elongation. Our results show that similarly to other DNA damage 
respose proteins, ATR is interacting with the centrosome of the ciliated cells and its 
inhibition is associated with shortened cilia, indicating a different role of ATR that might 
be involved in retinal ciliopathies. 
 
 
 
  
The Role of ATR for Cilium Formation and Elongation in Retinitis Pigmentosa 
50 
 
2.2. Introduction 
Ataxia telangiectasia and rad-3 (ATR) is a gene that encodes for a serine-
threonine protein kinase. This protein and its partner ataxia telangiectasia mutated 
(ATM) display an important role in DNA damage response (DDR) (Zhang et al., 2007). 
While ATM is activated in the presence of double strand breaks, ATR is recruited 
during single strand breaks, due to the collapse of the replication forks (Sarkaria et al., 
1999, Zhang et al., 2007). In humans, mutations in ATR gene are associated with 
Seckel syndrome, a rare disease characterized by intra-uterine growth retardation, 
microcephaly, facial and osteoskeletal abnormalities as well as retinal degeneration 
(Guirgis et al., 2001). 
Our group has previously characterized a Seckel syndrome mouse model (ATR+/s) 
regarding its retinal phenotype. We found that the mutant animals displayed a massive 
destruction of the photoreceptor (PR) layer (Valdes-Sanchez et al., 2013). We also 
described that in WT mice ATR is present in the connecting cilia of PR and ATR+/s mice 
presented shorter cilia, suggesting that PR degeneration results from a cilia defect in 
those animals (Valdes-Sanchez et al., 2013).  
The primary cilium is an organelle that comes from the cellular membrane of most 
mammalian cells. It consists of an axoneme of nine doublet microtubules, extended 
from the basal body and derived from the centrosome (Satir et al., 2010). This 
organelle is present in a vast number of cells, including neuronal and retinal cells, 
including PRs (Satir et al., 2010, Drivas et al., 2013, Valdes-Sanchez et al., 2013). It is 
now known that this structure is involved in multiple cellular events, such as sensory 
mechanisms and inhibition of cell cycle by recruitment of the centriole (Satir et al., 
2010, Drivas et al., 2013). It is easy to understand that mutations that affect primary 
cilia are responsible for a selection of human diseases and developmental disorders, 
named ciliopathies (Drivas et al., 2013). There are several mutations associated with 
retinal ciliopathies already described (Wheway et al., 2014), but the most common are 
the ones in CEP290 gene that is associated with 20% of Leber Congenital Amaurosis 
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(LCA) cases (Drivas et al., 2013) and mutations in RPGR gene that is associated with 
X-linked Retinitis Pigmentosa (Hildebrandt et al., 2011, Wheway et al., 2014). 
Emerging evidences have described the involvement of other DDR genes with retinal 
ciliopathies, such as MRE11A, CEP164 and ZNF423, suggesting a close relationship 
between DDR proteins and functional cilium maintenance (Yuan et al., 2013, Wheway 
et al., 2014).  
In this work we aimed to understand if ATR is involved in ciliary function and 
therefore has a role in RP. Herein we present further data about the ciliary function of 
ATR besides its known function related with DNA damage checkpoint. Furthermore, we 
show that ATR seems to have a 60 kDa isoform responsible for ciliary function. 
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2.3. Materials and Methods: 
 
2.3.1. Antibodies 
Primary antibodies 
Anti-ATR (rabbit, Abcam); Anti-acetylated α-tubulin (mouse, Sigma); Anti-γ-tubulin 
(mouse, Sigma); Anti-CDK2 (rabbit, Santa Cruz Biotechnology) 
Secondary antibodies 
Alexafluor donkey anti-rabbit 594 (1: 500, Molecular Probes); Alexafluor donkey anti-
mouse 488 (1: 500 Molecular Probes); HRP-conjugated anti-rabbit (1:20 000, Sigma); 
HRP-conjugated anti-mouse (1:20 000, Sigma) 
 
2.3.2. Cell Lines 
In this study, the human immortalized retinal pigment epithelial cell line (hTERT RPE-1 
ATCC CRL4000)) was used as model of ciliated cells. It is known that RPE-1 cells are 
able to develop primary cilia under serum-starvation conditions (Spalluto et al., 2013). 
 
2.3.3. Primary cilium induction 
For primary cilia induction, RPE-1 cells were cultured with Dulbecco’s Modified Eagle 
Medium:F12 Mix (DMEM:F12, Sigma) supplemented with 1% of L-Glutamin (Sigma) 
and 1% of Penincillin/Streptomycin (Sigma), and were kept without Fetal Bovine Serum 
(FBS) for 48h, at 37º C and 10% CO2. Then, RPE-1 cells were either fixed for 
immunofluorescence, or collected for protein extraction and western blot analysis. 
 
2.3.4. Immunofluorescence  
RPE-1 cells were fixed in ice-cold methanol for 10 minutes. Coverslips were washed 
twice in PBS and permeabilized in 0.1% Triton X100/PBS for 15 minutes. The 
coverslips were blocked in 1% goat serum/PBS at room temperature for 1h. Double 
immunocytochemistry against ATR (1:100) and acetylated α-tubulin (1:500) or ATR and 
   Chapter 2 
53 
 
γ-tubulin (1:500) were performed for 1h at room temperature. Cells were washed then 
3 times in PBS, and incubated with the secondary antibody (1:500) at room 
temperature for 1 h. After a final 3 washes, coverslips were mounted on glass slides 
with Vectashield containing 4', 6'-diamidino-2-phenylindole (DAPI) (Vector Laboratories 
Ltd., Peterborough, United Kingdom). Images were obtained using a Leica confocal 
microscope with a 63 × objective, using the appropriate filter sets. 
 
2.3.5. Western blot 
Proteins were extracted in cold RIPA buffer containing protease and phosphatase 
inhibitor cocktails. The protein content was measured by the Bradford assay and the 
samples stored at -80 ºC. Thirty micrograms of each extract were separated in a 
denaturing 10% SDS–PAGE gel and the proteins transferred to a PVDF membrane 
and blocked using 5% NFDM or Superblock (Thermo) for 1 h. The ATR antibody was 
incubated overnight at 4 ºC (1:1000 dilution). Acetylated α-tubulin and γ-tubulin were 
incubated for 1h at room temperature (1:1000 dilution). Membrane was probed with an 
HRP-conjugated secondary antibody for 1 h at room temperature and the 
immunoreactive bands were detected by chemiluminescence, using an ECL plus kit 
(Amersham). 
 
2.3.6. ATR and γ-tubulin immunoprecipitation 
The immunoprecipitation was performed using IgG magnetic beads (Millipore), 
according with the manufacturer’s instructions. 20 µg of ATR and γ-tubulin antibodies 
were used to immunoprecipitate ATR and γ-tubulin, respectively. Equal amounts of IgG 
were used as control antibodies. The antibody-linked beads were incubated,overnight 
at 4º C, with 500 µg of whole cell extract of RPE-1 cultured with FBS (FBS+) or without 
serum (FBS-), washed three times with PBS-T (0.1%) and eluted with glycine buffer, 
pH 2, for western blot analysis. 
The Role of ATR for Cilium Formation and Elongation in Retinitis Pigmentosa 
54 
 
2.3.7. ATR inhibition and cilia length measurement 
For ATR inhibition, two known inhibitors were tested: caffeine (Sigma) and ETP-46464 
(Millipore). Caffeine was dissolved in distilled water at 72 mM. The caffeine solution 
was then added to the culture media in a final concentration of 2.5, 5 and 10 mM. ETP-
46464 was resuspended in DMSO at 21 mM and was added to the culture media in a 
final concentration of 10 nM. After an overnight incubation, the cells were either fixed 
(for immunofluorescence) or collected for protein extraction and western blot analysis. 
The cilia length was measured using ImageJ software. 
 
2.3.8. Statistical Analysis 
Statistical analysis was performed using the SPSS software, version 20. 
The values were expressed as mean ± the standard error of the mean (SEM). The 
differences between groups were examined for statistical significance using the t-test 
and one-way ANOVA test. A P-value of 0.05 denoted the presence of a statistically 
significant difference. 
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2.4. Results and Discussion 
 
2.4.1. ATR colocalizes with the centrosome of the ciliated cells 
Our prior studies using ATR+/s mouse model have shown that in the retina, ATR is 
located in the cilia of PRs and the mutant mice display shortened cilia, suggesting that 
the PR degeneration results from a cilia defect in those animals (Valdes-Sanchez et al., 
2013). To better understand the role of ATR in cilia formation and elongation we 
decided to use an in vitro model of ciliated cells. It was previously described that RPE-1 
cells are able to develop primary cilia under serum-starvation conditions (Spalluto et 
al., 2013). The RPE-1 cells were maintained under serum-starvation (FBS-) conditions 
for 48h and primary cilia formation was analyzed by immunocytochemistry. Our results 
show that, under FBS- conditions approximately 45% of the cells developed primary 
cilia, while under with serum conditions (FBS+) only about 5% of the cells developed 
this organelle (Figure 2.1).  
 
 
 
 
 
 
 
Figure 2.1: Percentage of RPE-1 cells presenting cilia after being cultured with (FBS+) 
or without (FBS-) serum. Result represents the mean of ciliated cells ± SEM of ≥ 100 
individual cells. ∗P<0.05, represents significant result obtained by unpaired two-sample 
t-tests. 
 
As expected, in FBS+ cultures ATR is located all over the nucleus of the cells. 
However, in FBS- cultures there is a decrease in the ATR staining in the nucleus and 
an accumulation of ATR signal in the base of the primary cilia (Figure 2.2).  
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Figure 2.2: Immunofluorescence staining of methanol fixed RPE-1 cells cultured with 
(FBS +) and without serum (FBS -). Under serum starvation RPE-1 cells develop 
primary cilia (arrow) and ATR is located at the base of the primary cilia (arrow head). 
DAPI (blue) stains nuclei, ATR is stained in red and green represents acetylated α-
tubulin. Magnification: 630x 
 
This result corroborate with our previous in vivo results, in which we described 
ATR to be located in the primary cilia of PR cells (Valdes-Sanchez et al., 2013), 
showing that in post-mitotic cells, ATR seems to play a different role.  
It was previously described by Zhang and co-workers that there is a strong co-
localization of ATR with the centrosome of the interphase non-ciliated HeLa cells 
(Zhang et al., 2007). Moreover, it is also known that the primary cilia start growing from 
the basal body which is, in fact, derived from the mother centriole of the centrosome 
(Satir et al., 2010). Based on these findings, we decided to confirm if the accumulation 
of ATR found in the base of the primary cilia of RPE-1 cells corresponds to the 
centrosome. We found that in the FBS- condition there is a total co-localization of the 
ATR signal with γ-tubulin signal (Figure 2.3 - lower panel). However, this was not 
evident in the cells under FBS+ cultures (Figure 2.3 - upper panel). This means that 
ATR is co-localizing with the centrosome of the cells that develop primary cilia. 
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Figure 2.3: Immunofluorescence staining of methanol fixed RPE-1 cells cultured with 
(FBS +) and without serum (FBS -).γ-tubulin (arrow) and ATR (arrow head) are co-
localized at the centrosome. DAPI (blue) stains nuclei, ATR is stained in red and green 
represents γ-tubulin. Magnification: 630x 
 
To confirm this result we decided to perform an immunoprecipitation of γ-tubulin to 
prove its interaction with ATR in the centrosome. Indeed we found that ATR is co-
immunoprecipitating with γ-tubulin in the cells cultured under serum-starvation 
conditions (Figure 2.4). However we were not able to detect ATR signal in the whole 
extracts of RPE cells cultured with serum (Figure 2.4). This result corroborates our 
immunofluorescence results in which we were only able to find co-localization of γ-
tubulin and ATR in FBS- condition, in which the cells develop primary cilia (Figure 2.3). 
Surprisingly, the co-immunoprecipitation result was not a 300 kDa fragment 
corresponding to the full length ATR. The co-immunoprecipitated fragment presents a 
molecular weight of approximately 60 kDa. This result can be explained by the 
presence of an isoform of the ATR protein that can probably be associated with cilia 
function, formation and elongation. 
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Figure 2.4: Immunoprecipitation of γ-tubulin and co-immunoprecipitation of ATR 
showing that ATR is only detected in the celular extracts cultured under serum-
starvation conditions (FBS-). (FBS +: cells cultured with serum; FBS -: cells cultured 
without serum). 
 
2.4.2. Inhibition of ATR (by caffeine) affects ciliary length  
To test the effect of ATR inhibition in cilia formation, we decided to test two 
different agents that were described to inhibit ATR function: caffeine (Hall-Jackson et 
al., 1999) and ETP-46464 (Toledo et al., 2011). 
ATR is known to be implicated in both S/M and G2/M checkpoints (Hall-Jackson et 
al., 1999). However, it was proved that in the presence of caffeine, cell cycle arrest 
induced by this checkpoints was showed to be suppressed (Hall-Jackson et al., 1999) 
suggesting that caffeine inhibits the catalytic activity of ATR (Sarkaria et al., 1999). We 
decided to test three different concentrations of caffeine (2.5, 5 and 10 mM) and 
evaluate the effect in ATR expression and cilia length. The western blot analysis of the 
RPE-1 cells cultured under FBS+ showed no significant changes with the addition of 
caffeine to the culture medium of the cells (Figure 2.5). Unexpectedly, we were not able 
to detect the 300 kDa fragment corresponding to the full length ATR. On the other 
hand, we observed a decrease in the full length ATR protein in a caffeine-dependent 
manner, as well as a reduction in the 60 kDa fragment (Figure 2.5), the fragment size 
that is co-immunoprecipitating with γ-tubulin, in the cells cultured in FBS - conditions. 
However, the caffeine treatment did not have effect on the mitotic CDK2 kinase, 
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showing that the effect of caffeine in the levels of ATR was not due to cell cycle re-
entrance (Figure 2.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Western blot analysis of RPE-1 cells cultured with (FBS+) or without (FBS-) 
serum and treated with increased concentrations of caffeine. In the FBS- cells treated 
with caffeine is possible to observe a decrease in ATR expression in a caffeine-
dependent manner.  
 
 
In order to evaluate the effect of caffeine in cilia length we performed a double 
immunocytochemistry against ATR and acetylated α-tubulin. Our results show that after 
the addition of caffeine to the culture medium of the cells cultured with FBS- there was 
a marked decrease in the cilia length in a caffeine-dependent manner (Figure 2.6). 
 
 
 
 
 
 
 
The Role of ATR for Cilium Formation and Elongation in Retinitis Pigmentosa 
60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: Immunofluorescence staining of methanol fixed RPE-1 cells cultured in 
FBS - showing a decrease in the ciliary length after treatment with 5 mM of caffeine. 
DAPI (blue) stains nuclei, ATR is stained in red and green represents acetylated α-
tubulin. Magnification: 630x 
 
 
 
Figure 2.7 shows that 5 mM of caffeine was the concentration that induced a 
stronger effect in the ciliary length, showing approximately 80% shorter cilia than the 
ones without treatment with caffeine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: Cilia measurement of the RPE-1 cells cultured without serum and treated 
with different concentrations of caffeine. It is possible to observe a significant reduction 
in the length of the cilia after culturing the cells with caffeine. Result represents the 
mean of cilia length ± SEM of ≥ 100 individual cilia. ∗P<0.05, one-way ANOVA. 
 
Those results were also confirmed by immunoprecipitation of ATR in the cytosolic 
fraction of RPE-1 cultured without FBS and treated with caffeine. Figure 2.8 shows that 
after the caffeine treatment there is a decrease in the amount of 60 kDa ATR fragment 
being immunoprecipitated.  
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Figure 2.8: Immunoprecipitation of ATR from citosolic extracts of RPE-1 cells under 
serum-starvation conditions (FBS -) showing a decrease in ATR after caffeine 
treatment (5 mM Caffeine). 
 
 
These finding leads us to believe that the 60 kDa isoform of ATR that is highly 
affected by caffeine treatment is involved in ciliary function. 
ETP-46464 was previously described to be a potent inhibitor of ATR an IC50 = 10 
nM (Toledo et al., 2011). We tested the effect of ETP-46464 in the cilia length of RPE-1 
cells. We found no differences regarding the cilia length (Figure 2.9).  
 
 
 
 
 
 
 
Figure 2.9: Immunofluorescence staining of methanol fixed RPE-1 cells cultured in 
FBS - showing no differences in the ciliary length after treatment with 10 nM of ETP-
46464. DAPI (blue) stains nuclei, ATR is stained in red and green represents 
acetylated α-tubulin. Magnification: 630x 
 
The western blot analysis revealed a slightly decrease in ATR expression not only 
in the 300 kDa full ATR protein, as well as in the 60 kDa fragment, which we expect to 
be involved in ciliary function (Figure 2.10). However, the decrease in the 60 kDa 
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fragment was not as evident as we observed after caffeine treatment (Figure 2.5). This 
can probably be the reason why there was not a visible reduction in the cilia length. 
 
 
 
 
 
 
Figure 2.10: Western blot analysis of RPE-1 cells cultured under serum-starvation 
conditions and treated (+) or not (-) with the inhibitor agent ETP-46464. In the treated 
cells is possible to observe a decrease in the full length ATR fragment (300 kDa) but 
this reduction is not so evident in the 60 kDa fragment.  
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2.5. Conclusion 
ATR is a DDR protein recruited during single strand breaks, leading to cell cycle 
arrest (Cimprich et al., 2008). Several animal studies have shown that complete 
depletion of ATR originates early embryonic lethality, showing its importance in 
maintaining genome integrity during DNA synthesis (Brown et al., 2000, Murga et al., 
2009). Its deletion in adult mice has been associated to age-related phenotypes, such 
as premature hair loss and graying, kyphosis, osteoporosis, and defects in 
spermatogenesis, due to stem and progenitor cell degeneration (Ruzankina et al., 
2007).  
In humans, mutations in ATR gene are responsible for Seckel Syndrome, a 
disease characterized by severe intra-uterine growth retardation, microcephaly, facial 
and osteoskeletal abnormalities (O'Driscoll et al., 2003). In our previous study using 
ATR+/s mice we found that ATR is essential for the postnatal development of the PR 
layer. Moreover we found that the mutant mice display shorter cilia compared with the 
WT mice (Valdes-Sanchez et al., 2013). A study performed in three siblings with 
Seckel Syndrome have found severe, early onset retinal degeneration, showing no rod 
and cone responses in the ERG (Guirgis et al., 2001). 
To better understand the retinal degeneration presented by ATR+/s mice we 
decided to evaluate the role for ATR in retinal cilium formation and elongation. 
In this work we show for the first time that ATR is associated with the centrosome 
of G0 RPE-1 ciliated cells, cultured under serum-starvation conditions. This result was 
confirmed by immunoprecipitation of the centrosomal marker γ-tubulin and co-
immunoprecipitation of ATR. Interestingly we found that the ATR fragment that was co-
immunoprecipitated with γ-tubulin was a fragment of approximately 60 kDa and not a 
300 kDa fragment corresponding to the full length ATR. This 60 kDa fragment can 
correspond to an alternative splicing isoform from ATR. According to the AceView 
database there are 12 ATR variants described so far 
(http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/av.cgi?db=human&c=Gene&l=AT
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R) and one of them (cataloged as ATR.cAug10) have the predicted size of our 
fragment. Further studies are being currently performed to understand if this variant 
corresponds to the 60 kDa fragment that we identified. 
The inhibition of ATR by caffeine induced not only a decrease in the 300 kDa full 
length ATR but also in the 60 kDa ATR fragment, in a caffeine dependent manner. With 
the inhibition of ATR by caffeine we observed a concomitant reduction in the cilia 
length. The immunoprecipitation of ATR in the cytosolic extracts of RPE-1 cells treated 
with caffeine, compared with the untreated ones showed a decrease in the 60 kDa ATR 
fragment. In humans, 95% of multi-exon genes suffer alternative splicing, generating 
proteins with potential different functions (Eksi et al., 2013). Examples of well-known 
splicing variants with different functions are the splicing variants of BCLX that are 
proapoptotic and anti-apoptotic (Revil et al., 2007). In these work, our results lead us to 
believe that the 60 kDa ATR isoform is involved in the ciliary function despite its well 
know DNA damage repair role. 
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3.1. Abstract 
 
In this study we aimed to understand if glucose transporter 1 (GLUT1) activity 
affects the secretion capacity of anti-angiogenic factor pigment epithelium-derived 
factor (PEDF) by the retinal pigment epithelium (RPE) cells, thus explaining the 
reduction of PEDF levels observed in patients with diabetic retinopathy (DR).  
Analysis of GLUT1 expression, localization and function was performed in vitro in 
RPE cells (D407) cultured with different glucose concentrations, corresponding to non-
diabetic (5 mM of glucose) and diabetic conditions (25 mM of glucose), further 
subjected to normoxia or hypoxia. The expression of PEDF was also evaluated in the 
secretome of the cells cultured in these conditions. Analysis of GLUT1 and PEDF 
expression was also performed in vivo in the RPE of Ins2Akita diabetic mice and age-
matched wild-type (WT) controls. 
We have observed an increase in GLUT1 under hypoxia in a glucose-dependent 
manner, which we found to be directly associated to the translocation and stabilization 
of GLUT1 in the cell membrane. This stabilization led to an increase in glucose uptake 
by RPE cells. This increase was followed by a decrease in PEDF expression in RPE 
cells cultured in conditions simulating DR. Compared with non-diabetic WT mice, the 
RPE of Ins2Akita mice showed increased GLUT1 overexpression with a concomitant 
decrease in PEDF expression.  
Collectively, our data shows that expression of GLUT1 is stimulated by 
hyperglycemia and low oxygen supply, and this overexpression was associated with 
increased activity of GLUT1 in the cell membrane that contributes to the impairment of 
RPE secretory function of PEDF. 
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3.2. Introduction 
Diabetic retinopathy (DR), a blood-retinal barrier disorder, is the main complication 
of diabetes and the leading cause of blindness in working-age adults (Cheung et al., 
2010). The major pathological features at advanced stages of the disease are the 
abnormal neovascularization due to hypoxia, and blood leakage as a result of inner 
blood-retinal barrier breakdown (Cheung et al., 2010, Simo et al., 2010). The blood-
retinal barrier (BRB) is responsible for the homeostasis of the neuroretina and is 
composed by two different structures: the inner BRB (iBRB), formed by tight junctions 
between the endothelial cells of the retinal vessels, and the outer BRB (oBRB), formed 
by intracellular tight junctions in the retinal pigment epithelium (RPE) monolayer 
(Cunha-Vaz, 1979, Farjo et al., 2010, Gottfried et al., 2013). 
Most of the studies on the pathophysiology of DR focused their research in the 
iBRB breakdown and neuroretina damage (Kumagai et al., 1995, Knott et al., 1996, 
Badr et al., 2000, Duffy et al., 2006), with little attention on the effects of diabetes on 
the oBRB and RPE cells. Since the RPE is responsible, among others, for the transport 
of nutrients, such as glucose, ions and water, and secretion of factors crucial for the 
homeostasis of the neuroretina such as the pigment epithelium-derived factor (PEDF) 
and vascular endothelial growth factor (VEGF) (Simo et al., 2010, Xu et al., 2011), its 
role on DR is worth investigating. The healthy eye is characterized by low levels of 
angiogenic VEGF and high levels of anti-angiogenic factors, such as PEDF (Farjo et 
al., 2010). This balance is disrupted by ischemia during the pathogenesis of DR, 
increasing the ratio of angiogenic to anti-angiogenic factors and promoting abnormal 
neovascularization in the retina (Farjo et al., 2010). During ischemia, increasing levels 
of the heterodimeric hypoxia-inducible factor-1 (HIF-1) are detected (Catrina et al., 
2004, Hughes et al., 2010). Both HIF-1 subunits are constitutively expressed, but in 
normoxia conditions the HIF-1α subunit is rapidly degraded by an oxygen-dependent 
mechanism (Wang et al., 1995). However, in a hypoxic environment both HIF-1 
subunits are able to form dimers and translocate to the nucleus, where they can induce 
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the transcription of a wide range of genes (Huang et al., 1996, Kallio et al., 1997, Ke et 
al., 2006) including VEGF (Levy et al., 1995), EPO (Semenza et al., 1991), and the 
glucose transporter 1 (GLUT1) (Chen et al., 2001). 
GLUT1 is one of the 12 GLUT isoforms described (Shah et al., 2012), composed 
by a glycoprotein with 12 transmembrane domains and a single N-glycosylation site. 
GLUT1 is able to transport glucose bi-directionally across the cell membrane based on 
a concentration gradient (Bell et al., 1990, Shah et al., 2012). In the retina, as in the 
brain, glucose is the only fuel source for cells, and in both tissues glucose is 
transported to cells exclusively through the GLUT1 transporter (Sone et al., 2000, Shah 
et al., 2012). 
In this study we aimed to establish a correlation between RPE, GLUT1 and their 
role in diabetic retinopathy. Our hypothesis is that under diabetic conditions, where 
there is an increase in glucose and local hypoxia the expression of GLUT1 in RPE cells 
is increased, and that can affect the secretory function of RPE, namely their production 
of PEDF. This change in PEDF secretion can lead to an imbalance between VEGF and 
PEDF, contributing to diabetic retinopathy. To test our hypothesis, we studied the effect 
of both hyperglycemia and hypoxia on the cellular localization and expression of 
GLUT1 and PEDF expression on RPE cells, and further confirmed our findings in a 
mouse model of diabetic retinopathy. 
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3.3. Materials and Methods 
 
3.3.1. Cell lines 
D407, a human retinal pigment epithelial (RPE) cell line (Davis et al., 1995) used in the 
in vitro experiments was kindly provided by Dr. Jean Bennett from the University of 
Pennsylvania (USA). Cells were kept in culture in a humid chamber with 5% CO2 at 
37ºC and were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma-Aldrich, 
USA) supplemented with 1% Penicillin/Streptomycin (Sigma-Aldrich), 1% glutamine 
(Sigma-Aldrich) and 5% foetal bovine serum (Sigma-Aldrich). Culture medium was 
changed every 2 days. For the experiments on the glucose effect, cells were cultured in 
22.1 cm2 plates (TPP, Switzerland) for 3 days either in DMEM containing 5 mM D-
Glucose (to simulate normoglycemia) or in DMEM with 25 mM of D-Glucose (to 
simulate hyperglycemia). Cells were also grown in DMEM containing 5 mM of D-
Glucose in which mannitol was added up to a final concentration of 25 mM. Mannitol 
was chosen as an osmotic control because it is a carbohydrate with no biological 
activity and cannot be used by the cells as source of energy (Ellis et al., 1941, Duffy et 
al., 2006). Hypoxia was induced by addition of desferrioxamine (Aprelikova et al., 2004, 
Triantafyllou et al., 2006) (DFO, Sigma-Aldrich) to the culture media at a final 
concentration of 100 µM. After 16h of incubation with DFO, cells were collected for 
Western blot and immunocytochemistry for GLUT1. 
 
3.3.2. Detection of GLUT1 expression by Western blot 
Whole cell proteins were extracted in cold RIPA buffer (50 mM Tris-HCl pH 7.4, 1% 
NP-40, 0.25% Na-deoxycholate, 150 mM NaCl and 1 mM EDTA) supplemented with 
protease inhibitor cocktail (Roche, Germany). For isolation of the membrane/soluble 
fractions, cells were extracted in cold homogenization buffer (20 mM HEPES pH 7.4; 1 
mM EDTA; 250 mM sucrose) containing a protease inhibitor cocktail. The lysate was 
cleared by centrifugation at 4 ºC for 10 minutes at 3500 rpm. The supernatant was 
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centrifuged at 35 000 rpm for 1 hour at 4ºC, and the pellet corresponding to the 
membrane fraction, was suspended in buffer (10 mM HEPES pH 7.4; 250 mM sucrose) 
supplemented with a protease inhibitor cocktail. Protein content was measured by the 
Bradford assay and samples stored at -80 ºC. Thirty micrograms of each extract were 
separated in a denaturing 12% SDS–PAGE gel, the proteins transferred to a PVDF 
membrane (Amersham, UK), and blocked using Superblock Blocking buffer (Thermo 
Scientific) containing 0.1% of Tween-20 (Sigma-Aldrich, USA) for 1h at room 
temperature. GLUT1 antibody (ab32551; Abcam, UK) was incubated overnight at 4 ºC 
(1:2000 dilution) and β-Actin (A5441, Sigma-Aldrich) was incubated for 1h at room 
temperature (1:10000 dilution). The membrane was probed with an HRP-conjugated 
secondary antibody for 1 h at room temperature and the immunoreactive bands were 
detected by chemiluminescence, using an ECL Plus kit (Amersham). 
 
3.3.3. Cellular localization of GLUT1 by immunocytochemistry 
The cells were fixed in ice-cold methanol for 10 minutes, washed twice in PBS, and 
blocked in 1% goat serum/PBS at room temperature for 1h. Incubation with the GLUT1 
antibody (1:250) was performed for 1h at room temperature, followed by a wash step 
and incubation with the secondary antibody (Alexa Fluor® 594; 1:500; Life 
Technologies, USA) at room temperature for 1 h. Coverslips were mounted on glass 
slides with Fluoromount G (SouthernBiotech, USA) containing DAPI. Images were 
obtained using an AxioVision microscope with a 63× objective, using the appropriate 
filter sets (Axio Observer Z2, Zeiss). 
 
3.3.4. Glucose consumption assay 
For determining glucose consumption by glucose depletion from the culture medium, 
D407 cells were seeded at a density of 7.0 × 105 cells/well in 6-well flat-bottom tissue 
culture plates and maintained for 72h in culture medium containing 25 mM of D-
Glucose. A sample of culture medium was collected from each well and glucose 
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concentration was determined spectrophotometrically using the Glucose (GO) Assay 
Kit (Sigma-Aldrich), following the manufacturer’s instructions. Culture medium with 25 
mM of D-Glucose was used as control. 
 
3.3.5. PEDF detection in the culture medium of the RPE cells 
The cells were grown as previously described and PEDF levels were detected by 
Western blot in the culture medium. Briefly, the supernatant was collected and four 
volumes of ice-cold acetone were added. After an incubation of 30 min at -20 ºC, the 
supernatant was centrifuged for 10 minutes at 13000g and decanted. The pellet 
containing the precipitated proteins was re-suspended in 1x Sample Buffer. Protein 
content was measured by the Bradford assay and thirty micrograms of each extract 
were separated in a denaturing 12% SDS–PAGE gel and transferred to a nitrocellulose 
membrane (Biorad). Equal amounts of protein were loaded in the gel, determined by 
Ponceau S staining of the membranes before blocking. Western blot was performed as 
described previously, using a PEDF antibody (07-280, Merck Millipore; 1:1000). 
 
3.3.6. Animals 
For the in vivo experiments, male C57BL/6 (wild-type) and C57Bl/6 Ins2Akita (diabetic) 
mice (The Jackson Laboratory, USA) 2, 4, 7, and 10 months after the onset of 
hyperglycemia (two months after birth) were used. The animals were housed under 
controlled temperature, a 12 h light/dark cycle with food and water ad libitum. Diabetic 
phenotype was confirmed 2 months after birth by measuring blood glucose levels in a 
drop of blood from a tail puncture (Freestyle Precision, Abbot, USA), with animals used 
in this study exhibiting blood glucose ≥ 500 mg/dl. All experimental procedures were 
carried out according to the Portuguese and European Laboratory Animal Science 
Association (FELASA) Guide for the Care and Use of Laboratory Animals, the 
European Union Council Directive 2010/63/EU for the use of animals in research and 
the guidelines of the Association for Research in Vision and Ophthalmology (ARVO) for 
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the use of animals in ophthalmic and vision research. Animals were humanely 
sacrificed by cervical dislocation and the eyes enucleated. The RPE was isolated by 
dissection of the eyeball and homogenized in ice-cold RIPA buffer.  
 
3.3.7. Statistical analysis  
All experiments were performed in triplicate and the results expressed as mean ± 
standard error of the mean (SEM). Statistical analysis was performed with GraphPad 
Prism software. A value of P<0.05 was considered to be statistically significant. 
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3.4. Results 
 
3.4.1. Hypoxia induces overexpression of GLUT1 in RPE cells 
To evaluate the effects of glucose and ischemia in GLUT1 expression within the 
oBRB, we have used an in vitro setup using human RPE cells. D407 cells were 
cultured either with 5 mM of D-Glucose (corresponding to normoglycemia) or 25 mM of 
D-Glucose (corresponding to hyperglycemia) and further subjected to hypoxia by the 
addition of DFO, a chelating agent that induces hypoxia by inhibiting HIF-1α 
degradation at the proteasome (Aprelikova et al., 2004, Triantafyllou et al., 2006). We 
have confirmed that DFO does not induce cell death at the final used concentration of 
100 µM (data not shown). 
Figure 3.1 shows no differences at the protein level in cells in normoglycemic 
conditions under normoxia (N), when compared with hypoxia (H). On the other hand, 
there is a significant increase in GLUT1 protein in the cells cultured with 25 mM of D-
Glucose in hypoxia when compared with the cells cultured in normoxia, showing a 
direct effect of glucose concentration in GLUT1 expression. 
Figure 3.1: Effect of glucose and hypoxia in GLUT1 expression. Western blot analysis 
of GLUT1 in D407 RPE cells cultured under normoxia (N) and hypoxia (H) conditions 
and different concentrations of glucose in the culture medium: 5 mM of D-Glucose 
(corresponding to normoglycemia), 25 mM of D-Glucose (corresponding to 
hyperglycemia) and 25 mM of mannitol (osmolarity control). Quantitative data was 
obtained by normalization with β-Actin bands. N=4. *P<0.05 represents a significant 
difference in GLUT1 levels in cells cultured under hypoxia with high glucose 
concentration medium, determined by Tukey’s multiple comparisons test. 
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3.4.2. GLUT1 translocation to the cell membrane of RPE cells increases in 
response to hypoxia 
To determine if the increase in GLUT1 expression observed in figure 1 
corresponded to an increase in the transport of glucose, we have first determined the 
cellular localization of GLUT1 in human RPE cells by immunocytochemistry. The 
results show a significant increase in the accumulation of GLUT1 in the membrane of 
cells under hypoxia compared with cells under normoxia (Figure 3.2). Again, we 
observed GLUT1 staining to be stronger in cells in hypoxia and hyperglycemia 
compared with cells in hypoxia and normoglycemia.  
 
Figure 3.2: Immunocytochemistry for GLUT1 in RPE cells. D407 cells were cultured 
with different concentrations of glucose and subjected to hypoxia and normoxia. 
Staining for GLUT1 (red) shows higher intensity in the cell membrane of cells subjected 
to hypoxia. DAPI (blue) represents the nuclei. Magnification: 630X, scale bar: 20 µM 
 
We have confirmed these results by Western blot analysis of the membrane and 
soluble fractions of RPE cells cultured in high glucose either in normoxia or hypoxia 
(Figure 3.3). In Figure 3.3, it is clear the marked increase of the GLUT1 transporter in 
the membrane of cells in hypoxia compared to normoxia, which correlates with the 
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results in Figure 3.2. We could not observe an increase of GLUT1 in the soluble 
fraction of cells in hypoxia, which was expected since GLUT1 is a membrane 
transporter.  
Figure 3.3: GLUT1 expression is stabilized in the cell membrane in response to 
hypoxia. GLUT1 protein levels in the soluble and membrane fraction of D407 cells 
cultured with 25 mM of D-Glucose and subjected to normoxia and hypoxia, show a 
marked increase in GLUT1 expression in the membrane of cells cultured in hypoxic 
conditions. N=3. *P<0.05 symbolizes a significant increase in GLUT1 expression in the 
membrane fraction of the cells cultured under hypoxia with high glucose concentration 
medium, determined by Sidak’s multiple comparisons test. 
 
 
3.4.3. Glucose consumption is affected by hypoxia 
Based on the finding that GLUT1 expression is increased in the cell membrane of 
the RPE cells subjected to hypoxia, it was necessary to determine if this translates into 
increased glucose uptake by RPE cells. GLUT1 activity was measured by glucose 
consumption through glucose depletion in the culture medium. We have found a 
significant increase in glucose consumption induced by hypoxia (Figure 3.4), with cells 
consuming 60% of the glucose present in the culture medium compared to the 40% 
consumption in normoxia. This shows a marked effect of hypoxia on glucose 
consumption in diabetic retinopathy conditions. 
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Figure 3.4: Glucose consumption by RPE cells. Glucose depletion from the culture 
medium was increased for cells cultured under hypoxia, compared with cells in 
normoxia. The results are expressed as percentage of the control (culture medium). 
N=6. *P<0.05 denotes a significant difference in glucose consumption by cells in 
hypoxia compared with cells in normoxia, determined by the two-tailed t-test. 
 
 
3.4.4. Secretory function of RPE cells is impaired by high glucose and hypoxia 
One of the main functions of RPE cells is the secretion of multiple trophic factors 
essential for the maintenance and integrity of the neuroretina and choriocapillaries 
(Simo et al., 2010). One of these factors is PEDF, a neurotrophic and anti-angiogenic 
factor responsible for protecting neurons from ischemia-induced apoptosis (Takita et 
al., 2003) and inhibiting endothelial cell proliferation caused by VEGF (Hutchings et al., 
2002). We have evaluated the expression of PEDF in RPE cells cultured as described 
previously and found a significant decrease in PEDF levels for conditions where cells 
were cultured in hyperglycemia (25 mM glucose) and hypoxia (H) (Figure 3.5).  
This result shows that in diabetic conditions there is a decrease in the secretion of 
PEDF, which contributes to the disruption of the balance between the anti-angiogenic 
and angiogenic factors, as observed in human diabetic retinas (Boehm et al., 2003, 
Funatsu et al., 2006). 
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Figure 3.5: Effects of glucose and hypoxia in PEDF secretion by RPE cells. Western 
blot analysis of PEDF secretion in D407 cells cultured under normoxia (N) and hypoxia 
(H) conditions and different concentrations of glucose in the culture medium: 5 mM of 
D-Glucose (corresponding to normoglycemia), 25 mM of D-Glucose (corresponding to 
hyperglycemia) and Mannitol (osmolarity control). N=4. *P<0.05 represents a 
significant decrease in PEDF secretion by the RPE cells cultured under hypoxia with 
high glucose concentration medium, determined by Tukey’s multiple comparisons test. 
 
 
3.4.5. GLUT1 and PEDF expression is altered in the RPE of diabetic mice 
To confirm the validity of our in vitro findings, we have analyzed the expression of 
GLUT1 and PEDF in the RPE of wild-type and Ins2Akita diabetic mice (Figure 3.6). For 
all timepoints – 2, 4, 7 and 10 months after the onset of hyperglycemia – expression of 
GLUT1 was significantly increased in the RPE of diabetic mice compared with age-
matched wild-type animals. Additionally, we have found a marked decrease in PEDF 
levels in the RPE of the diabetic mice, especially at later ages. These in vivo results 
corroborate our in vitro results in which we found an increase in GLUT1 (Figure 3.1) 
and a decrease in PEDF secretion by RPE culls cultured in conditions simulating DR 
(Figure 3.5). 
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Figure 3.6: Secretory function of RPE is impaired in Ins2Akita mice. PEDF and GLUT1 
protein expression was assessed by Western blot of RPE tissue from diabetic mice 
with 2, 4, 7 and 10 months of hyperglycemia (HG) and compared with age-matched 
WT controls. Quantitative data was obtained by normalization of β-Actin bands and 
represents GLUT1 and PEDF expression in Ins2Akita related to WT (control). N=6. ns 
represents non-significant data determined by Sidak’s multiple comparisons test, P < 
0.05.  
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3.5. Discussion 
Diabetic retinopathy (DR) is one of the most frequent complications of Diabetes 
mellitus, affecting about 90% of patients with type 1 diabetes (Garg et al., 2009). It is 
known that hyperglycemia and ischemia are key factors for the progression of the 
disease (Farjo et al., 2010);  however the mechanism by which hyperglycemia 
contributes for the development of the disease remains unclear (Cheung et al., 2010). 
DR is traditionally characterized as a blood-retinal barrier disorder, in which the 
leakage of blood content, due to pathological neovascularization, is the main feature of 
the disease (Cheung et al., 2010). While the iBRB breakdown has been extensively 
investigated, the effects of diabetes on the RPE cells composing the oBRB are still not 
well known (Simo et al., 2010). The RPE monolayer is extremely important to maintain 
the homeostasis of the neural retina (Simo et al., 2010) suggesting that its impairment 
can compromise the retinal function. 
The retina is one of the most metabolically active tissues in the human body and 
glucose is its only source of energy (Chiu et al., 2011). In the retina, glucose transport 
is exclusively mediated by the glucose transporter 1 (GLUT1) (Kumagai et al., 1995). 
To better characterize GLUT1 expression in conditions of DR, we have devised a 
series of in vitro experiments using D407 cells, a spontaneously transformed human 
retinal pigment epithelial (RPE) cell line derived from a primary culture of human RPE 
cells (Davis et al., 1995). These cells are extensively used as in vitro models and are 
suitable to study molecular mechanisms of the RPE (Slomiany et al., 2004, Reinisalo et 
al., 2012). RPE cells were exposed to different concentrations of glucose to mimic 
normoglycemia (5 mM of D-Glucose) and hyperglycemia (25 mM D-Glucose). In 
addition, cells were also exposed to hypoxia to simulate retinal ischemia observed in 
DR patients (Farjo et al., 2010). It was previously shown that hypoxia induces 
overexpression of GLUT1 in mouse fibroblasts in response to metabolic adaptation 
(Chen et al., 2001), but there was no evidence regarding changes in GLUT1 
expression due to hypoxia in RPE cells. Our Western blot analysis showed no 
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differences in GLUT1 protein expression in the cells cultured with normoglycemic 
medium (Figure 3.1). In contrast, it is possible to observe that hypoxia induces a 
significant increase in GLUT1 protein levels in the cells cultured with 25 mM of D-
Glucose compared with the control cells cultured in normoglycemic (5mM of D-
Glucose) medium. This suggests that the diabetic environment induced by high 
glucose and hypoxia most likely contribute to the overexpression of GLUT1. Analysis of 
protein expression by immunocytochemistry shows an increase of GLUT1 staining in 
the cell membrane of the RPE cells in response to hypoxia (Figure 3.2). Similarly to the 
previous Western Blot results shown in Figure 3.1, the staining is stronger in cells 
cultured with 25 mM of D-glucose, which further supports the contribution of high 
glucose levels for the expression of GLUT1. To confirm this finding we have isolated 
both the membrane and soluble fractions of D407 cells cultured with 25 mM of D-
glucose. We have found a marked increase in GLUT1 expression in the membrane 
fraction of cells in hypoxic conditions when compared with cells cultured with the same 
glucose concentration in normoxia (Figure 3.3). Interestingly, the soluble concentration 
of GLUT1 is similar in both conditions, suggesting that the increase in GLUT1 
expression observed in the whole cell lysates (Figure 3.1) is due to an increase in 
GLUT1 expression in the cell membrane (figure 3.3). These results are in accordance 
to what was previously shown for GLUT4 in cardiomyocytes, where hypoxia induces a 
translocation of this protein to the cell membrane (Sun et al., 1994). It is known that in 
response to low levels of oxygen cells shift their glucose metabolism to anaerobic 
respiration, which is much less efficient (Wenger, 2002). The translocation of GLUT1 to 
the cell membrane can be a response to achieve a more effective glucose uptake in 
low oxygen conditions. To test this we have performed a glucose consumption assay in 
which the glucose remaining in the culture medium was measured in cells cultured 
under normoxia and hypoxia. Our results show that cells under hypoxia display higher 
glucose consumption compared with cells cultured under normoxia (Figure 3.4), 
showing an increase of glucose uptake by GLUT1 under hypoxia. 
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As previously stated one of the main functions of RPE cells is their secretory 
capacity, being responsible for producing and secreting a wide range of factors that 
support photoreceptors and guaranteeing optimal circulation and supply of nutrients 
(Strauss, 2005, Simo et al., 2010). One of those factors is PEDF, a neurotrophic and 
anti-angiogenic factor secreted by RPE cells that acts by inhibiting retinal endothelial 
cell growth and migration (Barnstable et al., 2004). 
Several studies have shown an imbalance between VEGF and PEDF levels in the 
vitreous of diabetic patients, showing that secretory function of RPE might be impaired 
(Ogata et al., 2002, Boehm et al., 2003, Funatsu et al., 2006). A significant decrease in 
PEDF secreted by cells cultured with high glucose and subjected to hypoxia is 
observed in Figure 3.5, showing that the increase in glucose uptake by GLUT1 has a 
negative impact in the PEDF expression. 
Our in vitro findings were also confirmed in vivo in the RPE of the diabetic Ins2Akita 
mice, comparing with non-diabetic WT mice. The Ins2Akita mouse is a non-obese model 
of type 1 diabetes that has been widely used as a model of DR (Barber et al., 2005, 
Gastinger et al., 2006, Han et al., 2013).This mouse model is considered a more 
reliable model to study DM complications as it develops spontaneously the disease 
(Barber et al., 2005) in contrast with STZ models. In Ins2Akita animals, hyperglycemia 
starts approximately at 4 weeks after birth, with retinal complications visible 
approximately 3 months after the onset of hyperglycemia, including vascular leakage, 
loss of pericytes, thickening of the inner retinal layers, (Barber et al., 2005) and 
increase of angiogenic markers such as VEGF (Han et al., 2013). 
In our study we have found a marked increase in GLUT1 expression in the RPE of 
diabetic mice, 4, 7 and 10 months after the onset of hyperglycemia, when compared 
with non-diabetic WT animals (Figure 3.6). This is consistent with the findings of Badr 
and co-workers in STZ-induced diabetic mice, where the fraction of glucose entering 
the retina is higher across the RPE than across the iBRB (Badr et al., 2000). 
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Diabetic retinopathy is usually characterized as a disease affecting primarily the 
retinal microvasculature, but its etiology is still not fully elucidated. We have found a 
significant decrease in PEDF expression in the RPE of diabetic mice, showing a 
significant impairment of the neurotrophic secretory function of RPE immediately after 
the onset of the disease. These results together with our in vitro results and work of 
others (Han et al., 2013), confirm the imbalance between pro- and anti-angiogenic 
factors in the retina of this diabetic mouse model. Although they observed no significant 
decrease in PEDF levels in the neuroretina (which excludes RPE) of diabetic mice 
before 7 months of hyperglycemia (corresponding to 9 months of age), we found a 
significant decrease in PEDF expression by RPE cells two months after the onset of 
hyperglycemia. This result points to the possibility that in DR the oBRB is affected 
before the iBRB. 
  
 
 
3.6. Conclusion 
Our data with RPE cells show an increase in GLUT1 expression in a glucose-
dependent manner under hypoxic conditions. This increase is associated with 
increased translocation, stabilization, and function of GLUT1 in the cell membrane of 
cells cultured under hypoxia compared with cells under normoxia. The increase of 
GLUT1 was associated to a decrease in PEDF production, showing an impairment of 
RPE secretory capacity. This was also confirmed in vivo, in which with an increase in 
GLUT1 and decrease in PEDF expression was also observed in the RPE of Ins2Akita 
diabetic mice.  
Further studies will focus on determining if this increase in GLUT1 expression and 
activity can explain the increase in levels of reactive oxygen species (ROS) (Kowluru et 
al., 2007) and advanced glycation end products (AGEs) (Singh et al., 2014). 
Additionally, our lab is studying if the well-studied up-regulation of VEGF by ROS, 
GLUT1 activity contributes to the impairment of PEDF secretion by RPE cells 
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AGEs (Lu et al., 1998, Sasaki et al., 2002) and hypoxia itself can contribute to the 
decrease in PEDF secretion by RPE cells, thus promoting the imbalance between 
PEDF and VEGF that is visible in patients suffering from DR. 
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4.1. Abstract 
Gene and cellular therapies are nowadays part of therapeutic strategies for the 
treatment of diverse pathologies. The drawbacks associated with gene therapy—low 
levels of transgene expression, vector loss during mitosis, and gene silencing—need to 
be addressed. The pEPI-1 and pEPito family of vectors was developed to overcome 
these limitations. It contains a scaffold/matrix attachment region, which anchors its 
replication to cell division in eukaryotic cells while in an extrachromosomal state and is 
less prone to silencing, due to a lower number of CpG motifs.  
Recent success showed that ocular gene therapy is an important tool for the 
treatment of several diseases, pending the overcome of the aforementioned limitations. 
To achieve sustained gene delivery in the retina, we evaluated several vectors based 
on pEPito and pEPI-1 for their ability to sustain transgene expression in retinal cells. 
These vectors stably transfected and replicated in retinal pigment epithelial (RPE) cells. 
Expression levels were promoter dependent with constitutive promoters 
cytomegalovirus immediate early promoter (CMV) and human CMV enhancer/human 
elongation factor 1 alpha promoter yielding the highest levels of transgene expression 
compared with the retina-specific RPE65 promoter. When injected in C57Bl6 mice, 
transgene expression was sustained for at least 32 days. Furthermore, the retina-
specific RPE65 promoter showed higher efficiency in vivo compared to in vitro.  
In this study, we demonstrate that by combining tissue-specific promoters with a 
mitotic stable system, less susceptible to epigenetic silencing such as pEPito-based 
plasmids, we can achieve prolonged gene expression and a sustained therapeutic 
effect. 
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4.2. Introduction 
Over the last decades, gene therapy has been a driving force for the development 
of strategies to treat genetic and acquired diseases. The major disadvantages of DNA-
based gene therapy are the epigenetic silencing due to unmethylated CpG motifs 
present in the bacterial backbone of plasmids grown in bacteria (Yew et al., 2002), and 
vector loss during mitosis, due to their incapacity to integrate the genome and replicate 
in the host cell (Conese et al., 2004, Jackson et al., 2006, Gill et al., 2009). The use of 
plasmids with the capacity to replicate in mammalian cells, less frequent silencing 
events and species/tissue-specific promoters could lead to sustained gene expression 
(Conese et al., 2004). To address these issues, Peichaczek and co-workers developed 
a new vector, named pEPI-1, which contains a scaffold/matrix attachment region 
(S/MAR), derived from the human interferon β-gene (Piechaczek et al., 1999). Other 
authors have shown the involvement of S/MARs in DNA duplex destabilization and 
strand opening, suggesting these sequences to be involved in DNA replication and 
gene expression (Bode et al., 2006, Giannakopoulos et al., 2009). Additionally, it was 
shown that S/MARs-containing vectors prevent epigenetic silencing of gene expression 
by shielding the transgene sequence from adjacent regulatory sequences and 
heterochromatinization (Argyros et al., 2008), maintaining the vector in a 
transcriptionally active state (Wong et al., 2011). The original pEPI-1 vector contains 
two mammalian transcription units and a total of 305 CpG motifs, most of them located 
in the elements of the vector required for bacterial propagation. To reduce the CpG 
content in bacterial backbone of pEPI-1 and obtain increased transgene expression in 
vitro and in vivo, a new non-viral vector, pEPito, was created by Haase and colleagues 
(Haase et al., 2010). pEPito was constructed by cloning the pEPI-1 plasmid replicon in 
a plasmid backbone containing 60% less CpG motifs and excluding the second 
transcription unit. A comparative study between pEPito and pEPI-1 constructs  showed 
pEPito-based vectors to be more efficient, both in vitro and in vivo (Haase et al., 2010), 
explained by CpG depletion of the bacterial backbone, which exhibits a strong 
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influence on epigenetic silencing events (Yew et al., 2002, Hyde et al., 2008, Bauer et 
al., 2010, Haase et al., 2010). 
The eye is an attractive target for gene therapy because it is an accessible and 
immune-privileged organ (Bloquel et al., 2006, Conley et al., 2008). Moreover, due to 
its small size, only a small amount of a therapeutic agent is necessary to observe a 
therapeutic effect (Bloquel et al., 2006). Diseases like glaucoma, retinitis pigmentosa 
(RP) and age-related macular degeneration (AMD) are blinding disorders that 
contribute to more than 25% of blindness cases, worldwide (Naik et al., 2009). The 
ineffectiveness of current treatments makes these diseases ideal targets for gene 
therapy (Bloquel et al., 2006, Naik et al., 2009). Moreover, in most of cases its genetic 
etiology is well known and there is easy access to the photoreceptors or RPE by 
localized injection (Musarella et al., 2011). Studies with viral vectors, based on adeno-
associated virus (AAVs), have as major limitation the small size of the therapeutic gene 
that can be incorporated into the viral vector (Kumar-Singh, 2008). Therefore, our goal 
is to combine a non-viral vector with an efficient gene expression system both in 
duration and expression levels, to overcome the need of repeated injections, thus 
increasing patient compliance. 
In this study, pEPI-1 and pEPito-based vectors were evaluated for their ability of 
sustained transgene expression both in vitro, in retinal pigment epithelial (RPE) cells 
and in vivo in the mouse retina. We found pEPito to be an excellent gene expression 
system, adequate for sustained gene expression. 
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4.3. Materials and Methods 
 
4.3.1. pEPI-1 and pEPito-based vectors 
Table 2 illustrates the five different plasmids tested in this study, which are based on 
pEPI-1 and pEPito vectors.  
 
 
 
The pEPI-1 vector contains a S/MAR sequence, derived from the human interferon β-
gene, two mammalian transcription units, and a CMV constitutive promoter. The 
derivative pEPito vectors contain a S/MAR sequence, and four different promoters: 
CMV promoter, human CMV enhancer/human elongation factor 1 alpha promoter 
(hCMV), human CMV enhancer/RPE65 (hCMV/RPE65), and RPE65, a RPE tissue-
specific promoter (Le Meur et al., 2007).  pEPito vectors also contain an eGFP-BSD 
cassette in which eGFP (enhanced green fluorescent protein) and BSD (blasticidin) are 
expressed through an IRES (internal ribosomal entry site). In addition to the promoter, 
the backbones of the vectors vary in CpG content and size (between 5.2 and 7.8 Kb). 
Chemically competent E. coli GT115 bacteria (Invivogen) were transformed using 30 
ng of each plasmid. Transformed bacteria were selected on LB-plates containing either 
ampicillin (Sigma) or kanamycin (Sigma). After bacterial propagation, pDNA was 
isolated using the QIAGEN® Plasmid Maxi Kit (QIAGEN), according to the 
Plasmid Size Backbone Promoter Transgene 
CpG motifs 
(backbone) 
pEPi-1 6.7 kb pEPi CMV eGFP 206 
pEPito-CMV-eGFP 5.3 kb pEPito CMV BSD-eGFP 37 
pEPito-hCMV-eGFP 5.2 kb pEPito hCMV BSD-eGFP 37 
pEPito-RPE65-eGFP 7.5 kb pEPito RPE65 BSD-eGFP 37 
pEPito-
hCMV/RPE65-eGFP 7.8 kb pEPito hCMV/RPE65 BSD-eGFP 37 
Table 2 – pEPI and pEPito vectors used in this study 
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manufacturer’s instructions. The restriction map of the plasmids was confirmed using 
endonuclease digestion and subsequent gel electrophoresis.  
 
4.3.2. Transfection Efficiency Assay 
In this study, the transfection efficiency of the plasmids was evaluated in a human RPE 
cell line, D407. This cell line was derived from an eyeball of a 12 year-old child (Davis 
et al., 1995). These cells have been extensively used as a model of the retina 
pigmented epithelium (Slomiany et al., 2004, Reinisalo et al., 2012). 
D407 cells were cultured in Dulbecco’s Modified Eagle Medium (Sigma) supplemented 
with 5% FBS (PAA), 1% of L-Glutamine (Sigma) and 1% Penicillin/Streptomycin 
(Sigma). 
For the transfection assay, 2x105 cells were seeded in a 6-well tissue culture plate 
(Orange Scientific).  Twenty-four hours after plating, the cells were transfected with 1 
µg of DNA and FuGENE® HD (Promega) as transfection reagent using a 3:1 (µL of 
FuGENE® HD:µg of DNA) ratio, according to the manufacturer’s instructions.  
Forty-eight hours after transfection, cells were suspended, washed three times with 
phosphate buffered saline (PBS) and GFP expression analyzed using a FACSCalibur 
(Becton Dickinson) device and JDS Uniphase® laser, with 100 000 events recorded. 
Controls included non-transfected cells cultured in the same conditions. 
 
4.3.3. Colony-forming Assay 
Fourty-eight hours post transfection, D407 cells were transferred from the 6-well tissue 
culture plate to 10 cm Petri dishes (BD Biosciences) and selected in the presence of 
blasticidin (Sigma). Due to conflicting reports in the literature regarding the blasticidin 
concentration for selection of stably transfected cells (Notari et al., 2006, Zhu et al., 
2009), we have determined the adequate blasticidin concentration to select D407 
transformed cells by a MTT assay where six different concentrations of blasticidin were 
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tested - 0.01, 0.1, 1, 3, 5 and 10 µg/mL. The selected concentration of blasticidin was 1 
µg/mL (please see supplementary data).  
After 32 days of selection with blasticidin, three colonies of each plasmid were 
extracted and maintained in culture for two additional months under selection (up to 
three months in total), with eGFP positive cells quantified by flow cytometry as 
described in the previous section. 
The remaining colonies were fixed with 4% paraformaldehyde (PFA, Sigma) in PBS, 
stained with 2% methylene blue in methanol (VWR) and counted.  
 
4.3.4. Injection of pEPito vectors in C57Bl6 mice and eGFP expression  
To test the in vivo efficiency of the pEPito-derived vectors, FuGENE® HD-plasmid 
complexes were injected into the eye of C57Bl6 mice pups. All methods involving 
animals were performed according to the ARVO Statement for the Use of Animals in 
Ophthalmic and Vision Research. Litters and nursing dams were housed in plastic 
cages in a pathogen-free environment, with continuous access to food and water on a 
12-hour light-dark schedule.  
The DNA-FuGENE complex used in vivo were prepared by mixing 2 µg of plasmid 
DNA and 1µL of FuGENE® HD in a total volume of 20 µL of PBS. Pups at postnatal 
age of 5 days (P5) were anesthetized on ice. Using a needle, the sclera was punched 
in the temporal side and 1 µL of the DNA-FuGENE complex was injected into the 
vitreous cavity. After the injection a topical ointment consisting of gentamicin and 
prednisolone acetate was applied to reduce the pain and the risk of infection. The 
contralateral non-injected eye was used as control. 
At 3, 7, 14, 21 and 32 days post injection (dpi), 8 mice per plasmid DNA were 
humanely sacrificed, the eyes enucleated and fixed in ice-cold 4% PFA in PBS, for 24 
hours. This was followed by overnight immersion in 30% sucrose (Sigma) in PBS and 
embedded in OCT (Tissue-Tek), for cryosection. 10 µm thick serial sections were 
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performed, counterstained with DAPI and mounted with Fluoromount G (Electron 
Microscopy Sciences). 
In vivo transfection was evaluated by eGFP expression using an AxioImager Z2 
Fluorescence microscope (Zeiss), with AxioCam HRm and magnifications of 50x and 
200x. The transfected area was quantified using ImageJ software, by quantifying both 
the GFP-positive and the ganglion cell layer areas, and calculating the percentage of 
GFP-positive area relative to the ganglion cell layer area. 
 
4.3.5. Statistical analysis  
Statistical analyses were performed using the SPSS Software, version 19.0. One-way 
ANOVA was used to compare the in vitro transfection efficiency of the different 
plasmids and the in vitro colony-forming efficiency of stably-selected D407 cells. In the 
event of a signiﬁcant ANOVA, Tukey test was used for post hoc analysis. 
Data are expressed as means ± standard deviation and *p<0.05 
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4.4. Results 
 
4.4.1. Transfection efficiency of pEPI-1 and pEPito vectors in RPE cells is 
promoter-dependent 
In vitro experiments were performed in human RPE cells, D407. The transfection 
efficiency was analyzed by flow cytometry of GFP-positive cells, 48 h post transfection. 
Our results for D407 cells showed that the plasmids pEPito-CMV, pEPito-hCMV 
and pEPI-1, containing either the CMV and hCMV constitutive promoters, presented 
transfection efficiencies in the range of 30% (Figure 4.1). The plasmid containing the 
hCMV enhancer element and the RPE65 promoter (pEPito-hCMV/RPE65) had the 
lowest transfection efficiency (6%), compared to the plasmids containing either the 
CMV or hCMV promoters (Figure 4.1). No GFP-positive cells were detected in cells 
transfected with pEPito-RPE65 (Figure 4.1). 
Due to the low transfection efficiency observed with pEPito-RPE65, this vector was 
not further tested. 
 
 
 
 
 
 
 
 
 
Figure 4.1: Transfection efficiencies for transiently transfected D407 cells with the 5 
different plasmids. Mean values are derived from four independent experiments and 
statistical significance was determined with One-Way Anova followed by a post hoc 
Tukey Test. The statistical difference is indicated by a star (*) symbol (*p<0.05). 
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4.4.2. pEPito plasmids express GFP for three months in mitotically active human 
RPE cells 
As previously stated, one of the major advantages of the S/MAR-containing 
plasmids is their ability to be maintained as an episome and to be replicated during 
mitosis (Wong et al., 2011), therefore avoiding one of the major drawbacks of plasmid 
gene therapy, which is the vector dilution effect, as cells divide, lesser number of cells 
will contain the plasmid with the gene of interest. To test the capacity of these plasmids 
to transfect cells and to be replicated during cell division, hence forming a stable 
transfected colony, D407 cells were transfected with pEPito-CMV, pEPito-hCMV and 
pEPito-hCMV/RPE containing the blasticidin resistance gene (BSD), for mammalian 
cell selection.  
Due to conflicting reports in the literature regarding the BSD concentration for 
colony selection, we have performed a MTT assay to determine the minimal BSD 
concentration to eliminate non-transfected cells and therefore select for pEPito-
modified cells. 
The ideal concentration of BSD to eliminate all untransfected cells, in one week, 
was 1 µg/mL (Figure 4.2). 
 
 
 
 
 
 
 
 
Figure 4.2: Relative percentage of D407 viable cells using different concentrations of 
BSD. C + is the positive control, without BSD; C - is the negative control, latex extract. 
Statistical significance was determined with one-way ANOVA followed by a post hoc 
Tukey test. The statistical difference is indicated by a star (*) symbol (*p < 0.05). BSD, 
blasticidin. 
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These results were further used for all selection experiments. All plasmids were 
able to originate stably transfected colonies of D407 cells (Figure 4.2). 
 
 
Figure 4.2: Bright field (A) and Fluorescence (B) microscopy of a stably transfected 
D407 cell line colony with pEPito-CMV-eGFP-BSD (1); pEPito-hCMV-eGFP-BSD (2) 
and pEPito-hCMV/RPE65-eGFP-BDS (3) 32 days post-transfection. 
 
 
The plasmid that led to a higher number of colonies after 32 days of selection was 
pEPito-hCMV, resulting in approximately 510 colonies (Figure 4.3). pEPito-CMV 
originated 360 colonies (Figure 4.3) and for pEPito-hCMV/RPE65, the number of 
colonies formed was markedly lower, resulting in about 200 colonies (Figure 4.3). This 
result was not surprising, as because pEPito-hCMV/RPE65 had a lower transfection 
efficiency, compared with the plasmids containing either the CMV or hCMV promoter. 
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Figure 4.3: Colony-forming efficiency of D407 cells selected with blasticidin, for each of 
the pEPito plasmids. Mean values are derived from three independent experiments and 
statistical significance was determined with One-Way Anova followed by a post hoc 
Tukey Test. Bars labeled with * indicate statistical difference (p<0.05). 
 
After one month of selection, the fluorescence of the colonies, observed by 
fluorescence microscopy, shows that the intensity of the fluorescence decreased over 
time in the colonies transfected with pEPito-CMV. On the other hand, in the colonies 
transfected with pEPito-hCMV, the intensity of fluorescence remained constant and 
high. These results were further confirmed by flow cytometry. After two months of 
selection, using a selection medium with BSD, about 19% of the cells transfected with 
pEPito-hCMV presented fluorescence (Figure 4.4 B). On the other hand, only 3% of the 
cells transfected with pEPito-CMV presented fluorescence (Figure 4.4 C) and in the 
cells transfected with pEPito-hCMV/RPE65 the eGFP expression was only detected in 
1% of the cells (Figure 4.4 D). After three months of selection, almost no eGFP positive 
cells were detected, in cells transfected with both pEPito-CMV and pEPito-
hCMV/RPE65 (Figure 4.4 G;H). In contrast, 2% of the cells transfected with pEPito-
hCMV remain fluorescent (Figure 4.4 F). 
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Figure 4.4: Flow cytometry of D407-colonies stably-transfected with pEPito-hCMV 
(B;F); pEPito-CMV (C;G) and pEPito-hCMV/RPE65 (D;H). Upper panels represent 
cells after two months of selection with BSD and lower panels corresponds to cells 
after three months of selection. A and E are the control non-transfected cells. 
 
 
4.4.3. pEPI and pEPito gene transfer to mouse retinas: 
An intravitreal injection of 1 µL of each plasmid using FuGENE® HD was 
performed in 5 days post-natal (P5) C57Bl6 mice. These results show absence of an 
inflammatory in the injected eyes, compared with the controls (non-injected 
contralateral eye) and a normal appearance. 
At 3, 7, 14, 21 and 32 dpi the GFP expression was analyzed in eye sections. Since 
the administration method was intravitreal injection, it was expected that the retinal 
ganglion cell layer was the one to be transfected, because it is in direct contact with the 
vitreous cavity we have indeed observed that the transfected cells expressing GFP 
were visible in clusters on the border of the ganglion cell layer (Figure 4.5). 
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Figure 4.5: Transversal sections of a mouse retina injected with pEPI-1 and pEPito-
based vectors, sacrificed 32 days post injection. * indicates clusters of eGFP-
expressing ganglion cells transfected with pEPito-hCMV (A) (Magnification: 50x); (B) 
corresponds to an amplification of image (A) (Magnification: 200x); pEPito-CMV (C) 
(Magnification: 200x); pEPI-1 (D) and pEPito-hCMV/RPE65 (E). F illustrates a non-
injected retina, without GFP expression. DAPI (blue) stains nuclei. GCL – Ganglion Cell 
Layer; INL – Inner Nuclear Layer; ONL – Outer Nuclear Layer. 
 
The overall analysis of the retinal sections showed that all the plasmids were able 
to express in vivo, up to 32 days after injection. Table 3 shows the number of retinas, 
per plasmid and per time-point, in which was possible to detect GFP expression. Since 
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it was not possible to follow the same animal along time, the results are shown as 
number of retinas (animals) with GFP expression. 
 
 
 
Overall, 3 dpi was the time-point in which less retinas exhibited GFP expression, 
as expected since it is a very short time period for the cell machinery to start the 
transcription of the genetic material within the plasmid. The number of retinas where it 
was possible to detect eGFP expression was reduced for pEPI-1 compared with the 
number of retinas injected either with pEPito-CMV or pEPito-hCMV. On the other hand, 
we observed a higher number of retinas displaying fluorescence in the eyes injected 
with pEPito-hCMV than with pEPito-CMV. Even in spite of the in vitro experiments 
using pEPito-hCMV/RPE65 had lower transfection efficiencies than those containing 
either CMV or hCMV promoter, this result was reversed in vivo, since the number of 
retinas expressing eGFP was comparable to the one observed for pEPito-hCMV. As 
expected, no fluorescence was detected in the retinas of the contralateral non-injected 
eye (Figure 4.5- F). 
After quantification, we conclude that the transfected area was about 1.5–2% of 
the GCL area. This area was not affected by the plasmid used. 
  
DPI pEPi-1 pEPito-CMV pEPito-hCMV pEPito-hCMV/RPE65 
3 1 0 4 3 
7 3 3 6 4 
14 4 4 5 5 
21 4 4 5 5 
32 3 3 5 4 
Table 3 – Summary of the number of GFP-positive retinas.  (N=8) 
 
DPI means days post-injection 
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4.5. Discussion  
The major disadvantages of pDNA-based gene therapy are the low transfection 
efficiency, the epigenetic silencing, due to the unmethylated CpG motifs present into its 
bacterial backbone (Yew et al., 2002), and the loss of the vector during mitosis, due to 
the incapacity of these vectors to integrate the genome of the host cell (Conese et al., 
2004, Jackson et al., 2006, Gill et al., 2009). The use of plasmids containing 
sequences that enable them to replicate in mammalian cells, such as plasmids 
containing S/MARs, with a minimum of unmethylated CpG motifs and species specific 
tissue promoters could lead to gene expression for longer periods of time. 
In this study, the potential of plasmids containing S/MARs, pEPI-1 and its 
derivative pEPito, as expression systems for gene transfer to the retina was tested in 
vitro and in vivo. The aim was to assess if these expression systems could display, in 
the retina, a prolonged and sustained expression, as observed for other tissues such 
as the liver (Argyros et al., 2008, Haase et al., 2010, Argyros et al., 2011, Wong et al., 
2011). 
Our transfection assay showed that for retinal cells D407, the constructs containing 
the RPE-specific were less effective than all the other constructs tested with either 
CMV or hCMV promoter, which presented a transfection efficiency of about 30%. All in 
vitro experiments were performed by transfecting equal amounts of plasmid (and not 
equimolar mass of DNA), this can account for differences regarding the increased 
transient transfection efficiencies observed for the smaller plasmids.  
To test the ability of these vectors to be replicated during mitosis, a colony-forming 
assay was performed, and all the plasmids were able to originate stably transfected 
colonies for at least 32 days post transfection. pEPito-hCMV originated the highest 
number of colonies and pEPito-hCMV/RPE65 the lowest. This result was expected 
because pEPito-hCMV/RPE65 had a lower transfection efficiency compared with the 
plasmids containing either CMV or hCMV promoter. Moreover, the cells extracted from 
the colonies transfected with pEPito-hCMV were able to maintain the GFP expression 
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for further two months, whereas in the colonies transfected with pEPito-CMV or pEPito-
hCMV/RPE65 no GFP positive cells were detected by flow citometry after this period. 
This result emphasizes the importance of the promoter in the expression profile of a 
plasmid, showing that the CMV promoter is more susceptible to silencing by epigenetic 
events than the hCMV promoter. Moreover, the plasmids are capable of stably 
replicate for over 100 cell divisions in vitro, which indicates that, in vivo, in retinal cells, 
mostly post-mitotic, gene expression will be maintained for long periods of time. 
In the in vivo assay, our results demonstrate that all the plasmids were able to 
express eGFP in mouse retinas for at least 32 dpi. The number of retinas expressing 
eGFP was lower for pEPI-1 than for pEPito-CMV or pEPito-hCMV. It was demonstrated 
that plasmids with a higher CpG content are more susceptible to epigenetic silencing 
events (Yew et al., 2002, Hyde et al., 2008, Bauer et al., 2010). Since the pEPI-1 
backbone has more CpG motifs than the pEPito backbone (Haase et al., 2010), our 
results are in agreement with the literature for other organs emphasizing the 
importance of a CpG-depleted vector for a sustained expression. On the other hand, 
we observed a higher number of retinas displaying fluorescence in the eyes injected 
with pEPito-hCMV than with pEPito-CMV. This is an accordance to what was described 
by Haase et al (Haase et al., 2010), which has shown these plasmids to originate the 
strongest luciferase expression in vivo, due to the fact that the hCMV promoter is less 
affected by epigenetic silencing events than CMV promoter (Hyde et al., 2008). 
Finally, although in our in vitro experiments pEPito-hCMV/RPE65 had lower 
transfection efficiency, the plasmid originates better results in vivo, highlighting the 
relevance of a tissue-specific promoter. Moreover, the expression of the pEPito-
hCMV/RPE65, containing a RPE-specific promoter observed in ganglion cells can be 
explained by the presence of the hCMV enhancer, which has been described as 
strongly potentiating gene expression. 
Our in vivo proof-of-principle study has shown lower efficiency than other studies 
where these systems were complexed with chitosan nanoparticles for corneal gene 
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delivery (Klausner et al., 2012), or using AAVs for retinal transduction (Wang et al., 
2011), it is important to highlight that the amount of DNA used in this study is much 
less than in the other studies. Our ultimate goal is to combine these very efficient 
systems with new nonviral vectors being developed in our lab. 
With this study we prove that these improved episomal vectors containing S/MARs 
and less CpGs - pEPito vectors - can be used for efficient gene transfer to the retina. In 
addition, the combination of an enhancer that is less affected by epigenetic silencing 
effects with a tissue-specific promoter, such as the hCMV-RPE65 promoter, is crucial 
to extend the transgene expression, in vivo, and contribute for an efficient gene 
therapy. 
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5.1. Abstract 
 
Diabetic retinopathy (DR) is one of the major complications of Diabetes mellitus. It 
is characterized by retinal microvascular changes caused by chronic exposure to 
hyperglycemia, leading to low tissue oxygenation and ultimately to neovascularization. 
Laser photocoagulation and vitrectomy are the most efficient treatments for DR, but 
display severe side effects such as the destruction of the healthy retina. Another 
clinical approach uses anti-angiogenic agents to prevent and delay progression of 
neovascularization, but these require recurrent local administrations which increase the 
possibility of retinal detachment, vitreous hemorrhage, and cataract formation. 
Studies in human diabetic retinas have revealed an imbalance between pro-
angiogenic factors such as the vascular endothelial growth factor (VEGF) and anti-
angiogenic factors, like pigment epithelial-derived factor (PEDF). This imbalance favors 
pathological angiogenesis contributing to DR, and can constitute a therapeutic target. 
Gene therapy was recently shown to be an adequate intervention for long-term 
treatment of several retinal pathologies. We have previously shown the newly 
engineered episomal vector pEPito to be able of sustained gene expression in the 
mouse retina. We here show that pEPito was able to overexpress PEDF for up to three 
months, both in in vitro cultures of human RPE cells, as well as in the retina of diabetic 
mice after a single subretinal injection. In vivo, in parallel with the increase in PEDF we 
observed a decrease in VEGF levels in injected compared with non-injected eyes and 
a significant effect on two hallmarks of DR: reduction of glucose transport (by glucose 
transporter GLUT1), and reduction of inflammation by decreased reactivity of microglia. 
Jointly, these results point to a significant therapeutic potential of gene therapy with 
pEPito-PEDF for the treatment of DR. 
 
Key words: Gene therapy; Diabetic Retinopathy; pEPito; PEDF; microglia; 
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5.2. Introduction 
 
Diabetes mellitus (DM) is a group of metabolic diseases characterized by high 
blood glucose that leads to several complications, including diabetic retinopathy (DR). 
DR is a progressive disease that features microvascular dysfunction due to chronic 
exposure to hyperglycemia (Cheung et al., 2010). Hyperglycemia is associated with a 
wide-range of biochemical events that contribute for the progression of the disease, 
such as accumulation of sorbitol, advanced glycation end-products (AGE), oxidative 
stress, protein kinase C activation, inflammation, up-regulation of the renin-angiotensin 
system and vascular endothelial growth factor (VEGF) (Cheung et al., 2010). 
Altogether, these mechanisms contribute to physiological changes in the retina, 
including capillary basement membrane thickening that induces pericyte and 
endothelial cell death, causing inner blood retinal barrier (BRB) breakdown. This loss of 
retinal capillary function leads to vascular wall leakage, inflammation and ischemia, 
contributing to retinal neovascularization, formation of microaneurysms, edema, and 
hemorrhages, which lead to irreversible blindness (Frank, 1995, Cheung et al., 2010, 
Chiu et al., 2011). 
Attempts to revert pathological neovascularization have focused on the inhibition of 
VEGF, since the increase in its levels causes changes in the BRB, resulting in retinal 
macular edema and neovascularization (Chiu et al., 2011). However, altered VEGF 
levels are not the single event associated with neovascularization: during DR, the 
balance between pro- and anti-angiogenic factors that inhibits pathological 
angiogenesis.is disrupted. This is caused by an up-regulation of angiogenic VEGF and 
down-regulation of the anti-angiogenic and neurotrophic factor pigment epithelial-
derived factor (PEDF), secreted by retinal pigment epithelial (RPE) cells (Broadhead et 
al., 2010, Farjo et al., 2010). PEDF has been shown to reduce neovascularization 
when administered as a protein to a mouse model of neovascularization (Yoshida et 
al., 2009, Liu et al., 2012). 
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Common treatments for DR are laser photocoagulation and vitrectomy; they can 
however cause retinal damage and permanent impaired vision, with the success of the 
treatment highly influenced by the disease progression stage (Fong et al., 2004).  
Recently, anti-VEGF agents, such as pegaptanib, ranibizumab and bevacizumab, have 
been shown to be more effective inhibiting NV than surgical approaches. The major 
disadvantage of these agents is their short half-life, which requires repeated intravitreal 
injections in order to obtain a sustained therapeutic effect (Vinores, 2006, Bakri et al., 
2007, Farjo et al., 2010, Praidou et al., 2010). To achieve a sustained therapeutic 
effect, one can turn to gene therapy, which has already been tested as a treatment for 
several retinal pathologies (Bainbridge et al., 2008, Maguire et al., 2009, MacLaren et 
al., 2014), including ocular neovascularization (Igarashi et al., 2003). Viral vectors, with 
overall limitations such limited size of the inserted gene, immune response, toxicity, 
and possible oncogenicity, are widely used for gene therapy. Alternative approaches 
encompass both non-viral vehicles and expression systems that can efficiently deliver 
and provide sustained gene expression. We have previously described the 
effectiveness of the self-replicating episomal vector, pEPito, in long-term gene 
expression in the mouse retina (Calado et al., 2014). Based on this study, we have 
used pEPito as an expression vector for PEDF to assess its potential for treatment of 
diabetic retinopathy. Using a two-fold approach - in vitro using human RPE cells and in 
vivo, using the Ins2Akita mouse model of DR – we aimed to determine if PEDF can 
constitute a therapeutic alternative for diabetic retinopathy. 
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5.3. Materials and Methods 
 
5.3.1. Vector construction 
pEPito-hCMV-eGFP-IRES-IB containing the human CMV enhancer/human elongation 
factor 1 alpha promoter was used as backbone, as described before (Haase et al., 
2010, Calado et al., 2014). Human PEDF was amplified with specific primers 
containing Nhe I (5’) and Bgl II (3’) restriction sites. The amplified fragment was 
digested with Nhe I and Bgl II and cloned in the pEPito-hCMV, digested with the same 
enzimes. The resulting construct was confirmed by restriction enzyme digestion and 
sequencing. The new plasmid pEPito-hCMV-PEDF with a 6.2 kb size was propagated 
in E. coli GT115. 
 
5.3.2. Evaluation of PEDF expression driven by the pEPito vector in vitro 
Human retinal pigment epithelial (RPE) cell line D407, used in the in vitro experiments, 
was kindly provided by Dr. Jean Bennett from the University of Pennsylvania (USA). 
Cells were kept in culture at 37 ºC in a humid chamber with 5% CO2 and were grown in 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma-Aldrich, USA) supplemented 
with 1% Penicillin/Streptomycin (Sigma-Aldrich), 1% glutamine (Sigma-Aldrich) and 5% 
foetal bovine serum (Sigma-Aldrich). Culture medium was changed every 2 days. 
Transfection was performed using FuGENE® HD (Promega) with a 3:1 (µL of 
FuGENE® HD:µg of DNA) ratio, according to the manufacturer’s instructions. Briefly, 
2x105 cells were seeded in a 6-well tissue culture plate (Orange Scientific) and 24h 
after seeding, cells were transfected with 1 µg of DNA. 24 h post transfection cells were 
transferred from the 6-well tissue culture plate to 6 cm Petri dishes. Once a week, for 
up to three months, the cells were subcultured and the samples of cells and culture 
medium collected for Western blot analysis. 
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5.3.3. Evaluation of PEDF expression driven by the pEPito vector in vivo 
Four-month old Ins2Akita (diabetic) mice (The Jackson Laboratory) housed under 
controlled temperature and a 12 h light/dark cycle with food and water ad libitum were 
used for the in vivo experiments. Diabetic phenotype was confirmed 2-months after 
birth by measuring blood glucose levels from a tail puncture (Freestyle Precision, 
Abbot), with animals used in this study exhibiting blood glucose ≥ 500 mg/dl. All 
experimental procedures were carried out according to the Portuguese and European 
Laboratory Animal Science Association (FELASA) Guide for the Care and Use of 
Laboratory Animals, the European Union Council Directive 2010/63/EU for the use of 
animals in research and the Association for Research in Vision and Ophthalmology 
(ARVO) for the use of animals in ophthalmic and vision research. Mice were profoundly 
anesthetized by intraperitoneal injection of Avertin®. 1uL of DNA (1 ug/uL) was injected 
in the subretinal space of the left eye by using an automatic pump injector (WPI) and 
electroporated using 7 mm tweezer electrodes (tweezertodes, Harvard Apparatus) 
connected to a BTX ECM 830 (Harvard Apparatus), as previously described (Matsuda 
et al., 2004). 
At 3-months post injection the animals were humanely sacrificed by cervical 
dislocation, the eyes enucleated, and processed depending on the experiment.  
 
5.3.4. Immunofluorescence for PEDF expression in vivo 
For immunohistochemistry, eyes were fixed with ice-cold 4% paraformaldehyde (4% 
PFA) in PBS overnight at 4 ºC, cryoprotected in 30% sucrose in PBS and embedded in 
OCT mounting medium (Tissue-Tek). Immunohistochemistry was performed either in 
10 µm thick serial sections or whole retinas. Briefly, the samples were washed in 0.1% 
Triton X100/PBS and blocked in 1% goat serum/PBS at room temperature for 1h. 
Incubation with the primary antibodies - rabbit polyclonal anti-PEDF 1:100; (Merck 
Millipore) and rabbit polyclonal anti-Iba1 (1:500; Wako) - was performed overnight at 
4ºC. 
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After incubation samples were washed 3 times in 0.1% Triton X100/PBS, and 
incubated with the secondary antibody (Alexa Fluor® 594; 1:500; Life Technologies, 
USA) at room temperature for 1 h. After 3 washes, slides were mounted with 
Fluoromount G (SouthernBiotech, USA) containing 4',6'-diamidino-2-phenylindole 
(DAPI). Images were obtained using an AxioVision microscope, using appropriate filter 
sets (Axio Observer Z2, Zeiss).  
 
5.3.5. PEDF expression by Western blot analysis 
Since PEDF is a secreted protein and PEDF-pEPito administration was performed 
subretinally, we evaluated its expression by Western blot in whole retinas and RPE 
cells. The latter were isolated by dissection of the eyeball and homogenized in ice-cold 
RIPA buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 0.25% Na-deoxycholate, 150 mM 
NaCl, and 1 mM EDTA) containing a protease inhibitor cocktail (Roche, Germany).  
Whole protein extract of D407 cells was also prepared using cold RIPA buffer 
supplemented with protease inhibitor cocktail. Protein content was measured by the 
Bradford assay and samples stored at -80 ºC. Thirty micrograms of protein extract 
were separated in a denaturing 12% SDS–PAGE gel, the proteins transferred to a 
PVDF membrane (Amersham, UK), and blocked using Superblock Blocking buffer 
(Thermo Scientific) containing 0.1% of Tween-20 (Sigma-Aldrich, USA) for 1h at room 
temperature. The primary antibodies used were rabbit polyclonal anti-PEDF (1:1000; 
Merck Millipore), rabbit polyclonal anti-VEGF (1:1000; Abcam), rabbit polyclonal anti-
GLUT1 (1:3000; Abcam), goat polyclonal anti-Iba1 (1:1000; Sigma-Aldrich), and rabbit 
polyclonal anti-GFAP (1:1000; Abcam), and were incubated overnight at 4 ºC. β-Actin 
was incubated for 1h at room temperature (1:10000; Sigma-Aldrich). The membrane 
was probed with an HRP-conjugated secondary antibody for 1 h at room temperature 
and the immunoreactive bands were detected by chemiluminescence, using an ECL 
Plus kit (Amersham).  
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Secreted PEDF was isolated from the culture medium by protein precipitation using 4 
volumes of ice-cold acetone for 1h, at -20ºC. After precipitation samples were 
centrifuged for 10 minutes at 13 000g, the supernatant decanted, and the pellet air-
dried for 30 minutes at room temperature. The pellet containing precipitated proteins 
was then re-suspended in 1x sample buffer and analyzed by Western blot. 
 
5.3.6. Statistical analysis  
All experiments were performed in triplicate and the results expressed as mean ± 
standard error of the mean (SEM). Statistical analysis was performed with GraphPad 
Prism software. A value of P<0.05 was considered to be statistically significant. 
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5.4. Results 
 
5.4.1. Characterization of PEDF in the retina of Ins2Akita diabetic mice 
Clinical studies have demonstrated a negative correlation between PEDF levels 
and the development of proliferative diabetic retinopathy (Zhu et al., 2012). To 
establish if Ins2Akita diabetic mice mimic what was observed in humans and are a valid 
animal model to evaluate PEDF effects, PEDF expression was evaluated in the retina 
of 4-month old Ins2Akita diabetic and compared to age-matched wild-type mice. As can 
be observed in Figures 5.1A and B, there is a significant decrease in PEDF expression 
in the retina of diabetic animals compared with wild-type ones, similar to what was 
observed in humans. This decrease is much more evident in the retinal pigment 
epithelium (RPE) of diabetic mice (Figure 5.1 C and D, compared with the expression 
in the neural retina. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: PEDF expression is significantly reduced in the retina of diabetic mice. 
PEDF protein expression was assessed by Western blot of inner retina (A) and RPE 
(C) tissue from diabetic and wild type (WT) mice. B and C represent quantitative data 
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normalized by the intensity of β-Actin bands. N=5, *P<0.05 represents significant 
differences in PEDF expression in the retina of Ins2Akita mice compared with the age-
matched WT mice, determined by the two-tailed t-test. 
 
5.4.2. pEPito enables long-term expression of PEDF in mitotic RPE cells 
For an efficient gene therapy strategy, the expression vector should be able of 
long-term and sustained levels of transgene expression. In our previous study we have 
described the effectiveness of the pEPito episomal vectors in sustained gene 
expression in retinal cells (Calado et al., 2014). We have also shown that plasmids 
containing the humanized CMV promoter (hCMV), known to be less affected by 
epigenetic silencing effects, were more efficient in promoting gene expression in retinal 
cells both in vitro and in vivo (Calado et al., 2014). Based on these results, we have 
chosen the pEPito-hCMV backbone to clone PEDF. We have found that our new 
construct was able to overexpress PEDF for almost three months in actively dividing 
human RPE cells (Figure 5.2).  
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Long-term expression of PEDF by D407 cells transfected with pEPito-
hCMV-PEDF. pEPito-hCMV-PEDF was able to overexpress PEDF for up to 77 dpt 
(days post-transfection) in mitotically active cells in levels significantly higher than 
those observed for non-transfected cells (NT). 
 
5.4.3. Restoration of PEDF protein levels in the retina of Ins2Akita mice 
Subretinal injection of a 1 µL solution of pEPito-hCMV-PEDF was performed into 
one eye of 4-month old Ins2Akita mice, with the contralateral eye remaining non-injected, 
as a control. Immediately after injection the eyes were electroporated to facilitate entry 
of the expression vector into the cell (Matsuda et al., 2004). After the procedure and 
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until sacrifice of the animal, the injected eyes had a normal appearance and absence of 
inflammation, similar to the non-injected, contralateral eye. 
The effect of PEDF overexpression was evaluated in the retina of the Ins2Akita 
diabetic mouse, a model of DR. Three months post injection, PEDF expression was 
analyzed in 10 micron eye sections, and immunohistochemistry shows an increase in 
PEDF detected in the injected eye, when compared with the contralateral non-injected 
one. Moreover, the intensity of PEDF expression was comparable to one observed in 
the WT mice (Figure 5.3).  
 
 
Figure 5.3: PEDF protein levels are restored after injection of pEPito-hCMV-PEDF. 
Retinal section of an Ins2Akita mouse eye injected with pEPito-hCMV-PEDF-IB three 
months post injection, showing PEDF levels comparable to age-matched WT mice. The 
contralateral, non-injected eye, exhibits a significant reduction in PEDF expression. 
DAPI (blue) stains nuclei and PEDF is marked red. Magnification: 400x 
 
These results were confirmed by Western Blot, with an increase in PEDF 
expression in injected compared with non-injected eyes. Moreover, the overexpression 
of PEDF in the retina of Ins2Akita diabetic mice was also associated with a decrease in 
other hallmarks of diabetic retinopathy, such as VEGF and glucose transporter 1 
(GLUT1) in the retina, as well as in the RPE (Figure 5.4). 
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Figure 5.4: Overexpression of PEDF driven by pEPito-hCMV-PEDF three months post 
subretinal injection in Ins2Akita mice. Expression of several markers relevant for the DR 
phenotype was analyzed in whole retinas and RPE cells. PEDF expression was 
significantly higher in injected animals, while VEGF (angiogenic factor), GLUT1 
(responsible for glucose uptake to the cell), Iba1 and GFAP (marker of microglia 
reactivity and indicator of inflammation, respectively) show reduction of their levels. 
 
One of the features observed in the Ins2Akita diabetic mouse is the activation of 
microglia evidenced by retracted and swollen projections (Zhu et al., 2009), which 
correlates with inflammation in the retina.  
To analyze for microglia activation as a marker of inflammation, we have 
performed immunohistochemistry for Iba1 (ionized calcium-binding adaptor molecule, 
Figure 5.5), specific for microglia and macrophages (Zhu et al., 2009). When compared 
with injected retinas (panel B), the microglia of non-injected retinas (panel A) has more 
retracted and swollen projections, a feature of reactive morphology of microglia. Iba1 
expression is decreased in the injected eyes (panel D) when compared with non-
injected (panel C), indicating that overexpression of PEDF has anti-inflammatory 
properties. 
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Figure 5.5: Overexpression of PEDF reduces microglia reactivity in the retina of 
diabetic mice. Whole mount retinas (upper panels, A and B) and section of an Ins2Akita 
mouse eye (lower panels, C and D) staining with Iba1. Panels of pEPito-hCMV-PEDF 
injected retinas three months post injection show migroglia with non-reactive 
morphology. Non-injected retinas display retracted and swollen projections, typical of 
reactive microglia. DAPI (blue) stains nuclei and Iba1 is stained in red. Magnification: 
400x. 
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5.5. Discussion 
Diabetic Retinopathy is a severely handicapping disease that affects 90% of type 1 
DM patients and 60% of type 2 DM patients,(Garg et al., 2009) and the leading cause 
of blindness in developed countries. Anti-VEGF agents used to treat neovascularization 
have shown to be effective in delaying the progression of the disease; however, due to 
their short half-life there is a need of repeated injections, with severe side-effects 
(Cheung et al., 2010). 
Neovascularization has been associated with an imbalance between VEGF, an 
angiogenic factor, and PEDF, an anti-angiogenic factor known to counteract VEGF 
function (Farjo et al., 2010). Targeting this imbalance can constitute an innovative 
therapeutic approach. To be an effective therapeutic strategy, the balance should be 
restored in the long-term, and gene therapy can achieve long-term expression. In the 
last decade, non-viral gene therapy vectors emerged as an alternative to viral vectors 
(Nayerossadat et al., 2012). A self-replicating episomal vector, pEPito, has been shown 
to replicate in mitotic cells while promoting long term gene expression (Haase et al., 
2010). More recently, our group has shown its effectiveness in transgene expression in 
the mouse retina (Calado et al., 2014).  
Based on our previous results with pEPito, in this study we have cloned the PEDF 
gene into the pEPito-hCMV backbone and tested the effectiveness of this vector both 
in vitro in human RPE cells, and in vivo in the Ins2Akita mouse model of diabetic 
retinopathy. The Ins2Akita mouse is a spontaneous non-obese model of type 1 diabetes 
that has been used to study DR (Barber et al., 2005, Gastinger et al., 2006, Han et al., 
2013). In these animals, hyperglycemia starts roughly at 8 weeks after birth and retinal 
complications are visible approximately 12 weeks after the onset of hyperglycemia, 
including vascular leakage, loss of pericytes, thickening of the inner retinal layers, 
inflammation (Barber et al., 2005), and increase of angiogenic markers such as VEGF 
(Han et al., 2013). 
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To test the therapeutic potential of our approach, we first needed to assess if the 
PEDF expression profile in diabetic Ins2Akita mice reproduces what is observed in 
humans. Our results show a significant decrease in PEDF expression levels in the 
inner retina of Ins2Akita mice compared with age-matched WT controls (Figure 5.1A-B). 
This was even more pronounced in the RPE of the diabetic mice (Figure 5.1C-D), 
showing that the secretion of PEDF by the retinal pigment epithelium (RPE) is affected 
in the early stages of the disease. This correlates well to what was described for 
humans (Boehm et al., 2003, Funatsu et al., 2006) 
Our in vitro results show that pEPito was able to overexpress PEDF for up to three 
months in mitotically active RPE cells, proving the mitotic stability of this episomal 
vector, and its long-term expression. These results were confirmed by Western blot of 
total cell lysates (data not shown) and secreted proteins present in the culture medium 
(Figure 5.2). Having shown that pEPito is capable of driving long-term PEDF 
expression, we aimed to determine if this can be achieved in vivo and consequently 
attenuate the DR phenotype. In the Ins2Akita diabetic mouse, a model of DR, our results 
show that the expression system was able to express PEDF for up to three months. As 
expected, PEDF overexpression was detected in the RPE layer of the retina of injected 
eyes, where the plasmid was delivered, and in the inner retina (Figure 5.3), since 
PEDF is a secreted protein. 
It was previously described that angiogenic VEGF is overexpressed in the retina of 
6-month old Ins2Akita diabetic mice (Han et al., 2013). Moreover, it was also described 
that intravitreal injection of PEDF was responsible for down-regulation of VEGF and 
inhibition of VEGF-VEGFR2 binding in the retina of the oxygen-induced retinopathy 
mouse model (Zhang et al., 2006). Similarly, our results show that overexpression of 
PEDF in the retina of Ins2Akita diabetic mice markedly decreases the expression of 
VEGF (Figure 5.4), compared with non-injected eyes, where VEGF levels are higher. 
Recent studies suggest that changes in the microglia, such as increased reactivity, 
are the early feature of DR (Grigsby et al., 2014). In with Ins2Akita diabetic mice, an 
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increase in retinal microglia immune reactivity was detected as early as 8 weeks after 
the development of hyperglycemia (Barber et al., 2005). This activation of microglia 
involves a series of proliferative, morphological, immunoreactive and migratory 
changes and can be used as a measure of the inflammatory status of the retina 
(Grigsby et al., 2014). We have evaluated microglia reactivity after injection of the 
pEPito-hCMV-PEDF and we found that the overexpression of PEDF strongly reduces 
microglial activity, visualized by the typical nonreactive morphology of microglia of long 
and thin cellular projections. In contrast, in the non-injected eye we have found the 
morphology typical of reactive microglia, characterized by retracted and swollen 
projections (Figure 5.5). These results are in accordance with a previous study, in 
which topical administration of PEDF peptide (PEDF78-121) in Ins2Akita mice prevented 
microglia activation (Liu et al., 2012). We have also found a decrease in GFAP 
expression in the injected eye, compared with the non-injected one (Figure 5.4). GFAP 
is an intermediate filament protein expressed by astrocytes, Müller and glial cells. In 
normal conditions glial cells express small amounts of GFAP; however after retinal 
injury, such as ischemia, glaucoma (Chang et al., 2007) and diabetes its expression 
increases (Barber et al., 2000). Our results show that treatment with PEDF decreases 
GFAP expression, which can be associated with a reversal in the retinal injury. 
Overall, this study demonstrates the beneficial effect of long-term expression of 
PEDF in the retina of diabetic mice, through the anti-inflammatory and anti-angiogenic 
potential of PEDF in preventing retinal complications of diabetes. 
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6. General Discussion 
 
Retinitis Pigmentosa (RP) and Diabetic Retinopathy (DR) are highly incapacitating 
genetic and acquired retinal disorders, respectively, affecting working-age adults 
(Cheung et al., 2010, Petrs-Silva et al., 2014). Despite the different etiology, they have 
in common the fact that there is no cure for either of them and the current treatments 
are ineffective and transient (Barnstable et al., 2004, Shintani et al., 2009, Cheung et 
al., 2010, Petrs-Silva et al., 2014). As such, gene therapy can constitute a therapeutic 
alternative for these diseases.  
Gene therapy strategies have been successfully applied in clinical trials for a wide-
range of retinal disorders, such as Leber’s Congenital Amaurosis (LCA), 
Choroideremia (CHM), and Age-related Macular Degeneration (AMD). In all these 
studies Adeno-Associated Viruses (AAV) are being used as vectors for gene delivery 
(Bainbridge et al., 2008, Maguire et al., 2009, Maclachlan et al., 2011, MacLaren et al., 
2014). However, in case of AAVs, their limited capacity of the inserted DNA limits their 
widespread use (Hauswirth et al., 2000, Cevher et al., 2012). Alternative approaches, 
including both non-viral vehicles and improved expression systems, that can efficiently 
deliver and provide sustained gene expression, are being investigated (Conese et al., 
2004, Gascón et al., 2013). 
The effectiveness of gene therapy is highly associated with the delivery method, 
which should be able to protect the gene of interest from the extra- and intracellular 
barriers, and the expression system that might provide prolonged gene expression 
without being integrated into host cell genome (Conese et al., 2004, Gascón et al., 
2013).  
In this project we aimed to develop a multifactorial strategy for efficient non-viral 
gene transfer to the retina. We intended to do this by i) identifying target genes for RP 
and DR, ii) cloning them in optimized self-replicating episomal expression systems 
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(pEPito), and iii) enhancing delivery to retinal cells by using a physical method, such as 
electroporation. 
In Chapter 2 we described ATR, a DNA damage response (DDR) protein, as being 
involved in cilia formation and elongation. Previous studies from the group of Shomi 
Bhattacharya demonstrated massive rod-cone photoreceptor (PR) degeneration, with 
pigment accumulation in mutants of ATR (ATR+/s), similar to the one observed in 
Retinitis Pigmentosa patients (Valdes-Sanchez et al., 2013). They also found that ATR 
is localized in the connecting cilium, corresponding to the centrosome of 
photoreceptors (Valdes-Sanchez et al., 2013). This unusual localization of ATR signal 
in PRs have been described also in other DDR proteins such as MRE11A, CEP164 
and ZNF423, which are associated with syndromic retinal degeneration (Anders et al., 
2011, Wheway et al., 2014). Thus, these results suggest that ATR, as well as other 
DDR proteins, might have a different role in post-mitotic cells, such as PRs. Herein we 
demonstrate that ATR is localized in the basal body (centrosome) of ciliated retinal 
pigment cells (Figure 2.3). This result was confirmed by immunoprecipitation of γ-
tubulin (centrosomal marker) with concomitant co-immunoprecipitation of ATR in the 
ciliated cells (Figure 2.4). 
Surprisingly the molecular weight of the protein co-immunoprecipitated with γ-
tubulin does not correspond to the full length protein (60 kDa and 300 kDa, 
respectively), pointing to a potential ATR isoform, specifically related with cilia function. 
The inhibition of ATR by caffeine induced a marked decrease in the full length ATR 
protein level, but especially in the 60 kDa fragment co-immunoprecipitated with γ-
tubulin (Figure 2.5 and 2.8). These results were followed by a 80% reduction in cilia 
length (Figure 2.6 and 2.7), proving that alterations in ATR expression influence cilia 
maintenance and function. In the future, it would be relevant to identify the 60 kDa 
fragment and, since it is co-immunoprecipitated with a centrosomal marker, try to 
understand its role in cell division and cilia formation and elongation.  
Chapter 6 
133 
 
According to the AceView database there is one isoform, named ATR.cAug10, 
which can correspond to our unidentified 60 kDa fragment 
(http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/av.cgi?db=human&c=Gene&l=AT
R). This isoform has 1664 bp long, one missing exon (Figure 6.1) and match with the 
antigen binding-site of the antibody used for the immunoprecipitation experiments 
(ab2905, Abcam). We are currently trying to identify the presence of this isoform in our 
samples. Our preliminary results show that the isoform is present in our ciliated cells in 
culture. We will try to clone and overexpress the isoform in retinal cells to track its 
cellular localization. In case it localizes in the cilium, we will confirm the size of the 
protein and attempt immunoprecipitation, sequencing and checking for interacting 
partners.  
 
Figure 6.1: Nucleotide Blast between ATR and ATR.cAug10 variant, showing its 
localization related to the full length gene and the missing exon. 
 
In a gene therapy context, it is desirable to overexpress both the full-length and the 
60 kDa ATR fragment in the retina of ATR+/s mutants to analyze the rescue of the 
retinal phenotype. In rescued animals, PRs degeneration should be halted or reversed. 
Chapter 3 is focus on molecular targets for treatment of DR. DR is characterized 
as a BRB disease, but while the effects of hyperglycemia and ischemia have been 
widely explored in the iBRB, its effects in the oBRB remain unclear. The oBRB is 
composed by the intracellular tight junction of the RPE cells (Cunha-Vaz, 1979). As 
previously described in section 1.2, one of the main functions of RPE is the production 
and secretion of neurotrophic and anti-angiogenic factors to maintain the homeostasis 
of the neuroretina. One of such factors is PEDF. Studies performed in PEDF KO mice 
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have shown that decreased levels of PEDF are associated with massive retinal 
neovascularization (Huang et al., 2008).  
It is well known that the key trigger for the development and progression of DR is 
the high blood glucose present in patients with Diabetes Mellitus (Cheung et al., 2010). 
In the retina, glucose uptake is exclusively performed by GLUT1 (Sone et al., 2000, 
Shah et al., 2012). Here we evaluated the direct effect of hyperglycemia and also of 
hypoxia, a consequence of hyperglycemia visible in diabetic patients (Bresnick et al., 
1975), in the transepithelial transport and the secretory capacity of RPE cells. Our 
results show that, under conditions simulating DR, there is an increase in GLUT1 
expression (Figure 3.1 and 3.6) and translocation to the cell membrane (Figure 3.3), 
contributing to an increase in glucose consumption (Figure 3.4). This was also 
associated with a decrease in PEDF production and secretion by the RPE cells, 
showing an impairment of RPE secretory function (Figure 3.5 and 3.6). In figure 6.2 we 
propose a mechanism by which diabetes can contribute to the loss of function of RPE 
cells.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2: Proposed mechanism by which the increase of GLUT1 can contribute for 
RPE impairment and progression of DR. 
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With the chronic exposure to hyperglycemia, there is increased microvascular 
damage, reducing retinal blood supply.  This contributes to retinal ischemia, increasing 
the expression and stabilization of Hypoxia Inducible Factor-1 (HIF-1) (Catrina et al., 
2004), which acts as a transcription factor for several genes, including GLUT1 (Chen et 
al., 2001) and VEGF (Levy et al., 1995). The increase of VEGF (Sone et al., 2000) and 
GLUT1 (as shown in this work) contribute to an increase in intracellular glucose which, 
in turn, might contribute to the increase of ROS (Kim et al., 2015) and AGE’s (Singh et 
al., 2014), upregulating VEGF expression (Lu et al., 1998, Sasaki et al., 2002), thus 
contributing to PEDF downregulation. The downregulation of PEDF aggravates the 
imbalance between PEDF and VEGF towards VEGF expression, inducing retinal 
neovascularization and later on, vision loss. 
Considering these results, we have identified PEDF as a therapeutic target for 
gene therapy to treat DR, further explored in Chapter 5. 
 As described in Chapter 1, the major limitation of non-viral vector is its transient 
gene expression and, due to that, low transgene levels are expressed (Cevher et al., 
2012, Nayerossadat et al., 2012). Efforts have been undertaken to improve expression 
systems to overcome these drawbacks (Conese et al., 2004, Gill et al., 2009). 
Examples are the development of minicircle DNA (mcDNA), Minimalistic 
Immunogenically Defined Gene Expression (MIDGE) vectors, plasmids free of 
antibiotic resistance gene (pFARs) and self-replicating episomal vectors, such as 
pEPito. Chapter 4 describes the use of pEPito vectors for long-term expression to the 
retina. We have tested several promoters combined with pEPito backbone, such as 
CVM promoter, hCMV promoter (a humanized CMV promoter containing less CpG 
motifs), and RPE tissue-specific promoter (pEPito-hCMV/RPE65) for a targeted 
therapy. We have found that the pEPito containing the hCMV promoter had higher 
mitotic stability (Figure 4.3) and a more prolonged expression, both in vitro (Figure 4.4) 
and in vivo (Table 3) when compared with the other promoter-pEPito constructs. We 
also found that, despite the low transfection efficiency in vitro of the plasmid containing 
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the tissue-specific promoter (pEPito-hCMV/RPE65), this was partially reversed in vivo. 
These results highlight the relevance of using low CpG containing promoters (such as 
hCMV and RPE65 promoter) for a sustained gene expression profile. As RPE65 
promoter is tissue-specific promoter for retinal pigment epithelium (RPE) cells 
(Boulanger et al., 2000, Boulanger et al., 2002), it would be most interesting to test the 
feasibility of these systems in rescuing models of RPE degeneration, such as forms of 
RP and DR. 
In Chapter 5 we combine the findings from Chapter 3 and 4 to develop an efficient 
non-viral gene therapy for DR. In Chapter 3 we described an increase of GLUT1 with a 
concomitant decrease in PEDF expression in the RPE of Ins2Akita diabetic mice. Based 
on the results obtained in Chapter 4, in Chapter 5 we have cloned the PEDF gene into 
pEPito-hCMV backbone. Our in vitro results confirmed the mitotic stability and long-
term expression of PEDF driven by pEPito-hCMV backbone in human RPE cells 
(Figure 5.2). In vivo, pEPito-PEDF was able to overexpress PEDF for up to three 
months in the retina of diabetic mice at levels comparable to age-match WT controls 
(Figure 5.3). The overexpression of PEDF in the retina and RPE of diabetic mice was 
followed by a decrease in the expression of several molecular markers of DR, such as 
GLUT1, vascular endothelial growth factor (VEGF), glial fibrillary acidic protein (GFAP), 
and ionized calcium-binding adapter molecule 1 (Iba1) (Figure 5.4 and 5.5), confirming 
the anti-inflammatory and anti-angiogenic capacity of PEDF in ameliorating 
complications of DR. Moreover, these results show that electroporation is an efficient 
and safe method for retinal gene delivery. In the future we intend to determine the 
amount of pEPito plasmids that are present in each retinal cell. Altogether, the results 
of this thesis will pave the way for a preclinical study, in which we will perform 
physiological as well as functional analysis of the rescue of the DR phenotype. These 
include eletroretinography (ERG), since Ins2Akita are characterized by having defects in 
scotopic a-wave, b-wave, and photopic b-wave amplitudes (Han et al., 2013), and 
optical coherence tomography (OCT) to measure retinal thickness, considering that the 
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diabetic mice display a significant reduction of the inner layers of the retina (Barber et 
al., 2005). 
Although much remains to be done, some issues that are currently a drawback for 
the success of non-viral gene therapy were addressed:  
i) Short-term/transient gene expression: the presence of S/MARs into pEPito 
backbone allows mitotic stability and long-term expression, in an episomal state. 
ii) Gene silencing: the removal of CpG content in pEPito backbone and promoter 
reduces epigenetic silencing events, thus promoting a prolonged gene expression 
profile. 
iii) Low transfection efficiency: using electroporation as a delivery method, we 
obtained high transfection efficiency in vivo, originating expression levels of therapeutic 
genes comparable to WT animals. 
Altogether, the multifactorial approach presented in this work supports the potential 
of non-viral gene therapy as a clinical alternative to viral gene therapy. 
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